secondary allylic alcohol - Ontology Report - Rat Genome Database

Submit Data | Help | Video Tutorials | News | Publications | Download | REST API | Citing RGD | Contact

Advanced Search (OLGA)

CHEBI ONTOLOGY - ANNOTATIONS

{{ watchLinkText }}

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:	secondary allylic alcohol	go back to main search page
Accession:	CHEBI:134396	browse the term
Definition:	An allylic alcohol in which the carbon atom that links the double bond to the hydroxy group is also attached to one other carbon and one hydrogen.
Synonyms:	related_synonym:	Formula=C3H2OR4; SMILES=C(C(=C()))(O)([H]); secondary allylic alcohols

show annotations for term's descendants Sort by:
Rat (333) Mouse (346) Human (330) Chinchilla (0) Bonobo (0) Dog (0) Squirrel (0) Pig (1) Green Monkey (0) Naked Mole-rat (0) All
Genes (333)

(4Z,7Z,10Z,13Z,15E,19Z)-17-hydroxydocosahexaenoic acid

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

arachidonate 15-lipoxygenase

multiple interactions

17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [[Dietary Fats co-treated with Cholesterol, Dietary] promotes the reaction [Silver Compounds results in decreased expression of ALOX15 mRNA]]

NCBI chr10:55,060,169...55,068,885
Ensembl chr10:55,060,412...55,068,874

G

arachidonate 5-lipoxygenase

decreases expression
multiple interactions

17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid results in decreased expression of ALOX5 protein
17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [[[Dietary Fats co-treated with Cholesterol, Dietary] results in increased susceptibility to Silver Compounds] which results in decreased expression of ALOX5 mRNA]

PMID:17056761 PMID:34601004

NCBI chr 4:149,531,329...149,578,696
Ensembl chr 4:149,531,515...149,578,743

G

C-C motif chemokine ligand 2

multiple interactions

17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [[Dietary Fats co-treated with Cholesterol, Dietary] promotes the reaction [Silver Compounds results in increased expression of CCL2 mRNA]]; 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [[Dietary Fats co-treated with Cholesterol, Dietary] promotes the reaction [Silver Compounds results in increased expression of CCL2 protein]]; 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [[Silver Compounds results in increased susceptibility to [Dietary Fats co-treated with Cholesterol, Dietary]] which results in increased expression of CCL2 mRNA]; 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [[Silver Compounds results in increased susceptibility to [Dietary Fats co-treated with Cholesterol, Dietary]] which results in increased expression of CCL2 protein]; 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Lipopolysaccharides results in increased secretion of CCL2 protein]; 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Silver Compounds results in increased expression of CCL2 mRNA]; 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Silver Compounds results in increased expression of CCL2 protein]

PMID:21724996 PMID:34601004

NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226

G

C-X-C motif chemokine ligand 2

multiple interactions

17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [[Dietary Fats co-treated with Cholesterol, Dietary] promotes the reaction [Silver Compounds results in increased expression of CXCL2 mRNA]]; 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [[Dietary Fats co-treated with Cholesterol, Dietary] promotes the reaction [Silver Compounds results in increased expression of CXCL2 protein]]; 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [[Silver Compounds results in increased susceptibility to [Dietary Fats co-treated with Cholesterol, Dietary]] which results in increased expression of CXCL2 mRNA]; 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [[Silver Compounds results in increased susceptibility to [Dietary Fats co-treated with Cholesterol, Dietary]] which results in increased expression of CXCL2 protein]; 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Dextran Sulfate results in increased expression of CXCL2 protein]; 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Silver Compounds results in increased expression of CXCL2 mRNA]; 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Silver Compounds results in increased expression of CXCL2 protein]; [Silver Compounds results in increased susceptibility to 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid] which results in increased expression of CXCL2 mRNA

PMID:21724996 PMID:34601004

NCBI chr14:17,181,030...17,183,075
Ensembl chr14:17,181,062...17,183,075

G

C-X-C motif chemokine ligand 3

multiple interactions

17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Dextran Sulfate results in increased expression of CXCL1 protein]

NCBI chr14:17,287,727...17,289,451
Ensembl chr14:17,270,146...17,289,511

G

intercellular adhesion molecule 1

multiple interactions

17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Dextran Sulfate results in increased expression of ICAM1 mRNA]

NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438

G

interferon gamma

multiple interactions

17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Lipopolysaccharides results in increased secretion of IFNG protein]

NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375

G

interleukin 1 beta

multiple interactions

17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Dextran Sulfate results in increased expression of IL1B protein]

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 6

multiple interactions

17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [[Dietary Fats co-treated with Cholesterol, Dietary] promotes the reaction [Silver Compounds results in increased expression of IL6 mRNA]]; 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [[Dietary Fats co-treated with Cholesterol, Dietary] promotes the reaction [Silver Compounds results in increased expression of IL6 protein]]; 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [[Silver Compounds results in increased susceptibility to [Dietary Fats co-treated with Cholesterol, Dietary]] which results in increased expression of IL6 mRNA]; 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [[Silver Compounds results in increased susceptibility to [Dietary Fats co-treated with Cholesterol, Dietary]] which results in increased expression of IL6 protein]; 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein]; 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Silver Compounds results in increased expression of IL6 mRNA]; 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Silver Compounds results in increased expression of IL6 protein]

PMID:21724996 PMID:34601004

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

integrin subunit alpha L

multiple interactions

17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Dextran Sulfate results in increased expression of ITGAL mRNA]

NCBI chr 1:181,918,183...181,955,735
Ensembl chr 1:181,918,183...181,955,732

G

myeloperoxidase

multiple interactions

17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Dextran Sulfate results in increased activity of MPO protein]; 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased activity of MPO protein]

NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819

G

NFKB inhibitor alpha

multiple interactions

17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Dextran Sulfate results in increased expression of NFKBIA mRNA]

NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941

G

peroxisome proliferator-activated receptor gamma

multiple interactions

17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid binds to and affects the activity of PPARG protein

NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468

G

prostaglandin-endoperoxide synthase 2

multiple interactions

17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 mRNA]

NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188

G

RELA proto-oncogene, NF-kB subunit

multiple interactions

17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Dextran Sulfate results in increased activity of RELA protein]

NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484

G

tumor necrosis factor

multiple interactions
decreases secretion

17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]; 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]
17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid results in decreased secretion of TNF protein

PMID:17056761 PMID:21724996

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

vascular cell adhesion molecule 1

multiple interactions

17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Dextran Sulfate results in increased expression of VCAM1 mRNA]

NCBI chr 2:204,038,120...204,057,852
Ensembl chr 2:204,038,114...204,057,958

16,16-dimethylprostaglandin E2

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

AKT serine/threonine kinase 1

increases phosphorylation
multiple interactions

16,16-Dimethylprostaglandin E2 results in increased phosphorylation of AKT1 protein
EGFR affects the reaction [16,16-Dimethylprostaglandin E2 results in increased phosphorylation of AKT1 protein]

NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921

G

BCL2 associated X, apoptosis regulator

increases response to substance
affects localization

BAX results in increased susceptibility to 16,16-Dimethylprostaglandin E2
16,16-Dimethylprostaglandin E2 affects the localization of BAX protein

NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368

G

epidermal growth factor receptor

multiple interactions

EGFR affects the reaction [16,16-Dimethylprostaglandin E2 results in increased phosphorylation of AKT1 protein]

NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382

G

15-hydroxyprostaglandin dehydrogenase

increases activity

16,16-Dimethylprostaglandin E2 results in increased activity of HPGD protein

NCBI chr16:33,986,265...34,024,228
Ensembl chr16:33,986,266...34,024,228

G

myeloperoxidase

multiple interactions

16,16-Dimethylprostaglandin E2 inhibits the reaction [Indomethacin results in increased activity of MPO protein]

PMID:11686837 PMID:11855677 PMID:11991626 PMID:18306037

NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819

G

nitric oxide synthase 2

multiple interactions

16,16-Dimethylprostaglandin E2 inhibits the reaction [Indomethacin results in increased activity of NOS2 protein]; 16,16-Dimethylprostaglandin E2 inhibits the reaction [Indomethacin results in increased expression of NOS2 mRNA]

PMID:11686837 PMID:11855677 PMID:11991626 PMID:15610444 PMID:18306037

NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210

G

prostaglandin-endoperoxide synthase 2

multiple interactions
increases expression

Flurbiprofen inhibits the reaction [16,16-Dimethylprostaglandin E2 results in increased expression of PTGS2 mRNA]
16,16-Dimethylprostaglandin E2 inhibits the reaction [SC 560 results in increased expression of PTGS2 mRNA]

PMID:9099957 PMID:15610444

NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188

G

tumor necrosis factor

multiple interactions

16,16-Dimethylprostaglandin E2 inhibits the reaction [Lipopolysaccharides results in increased expression of TNF]

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

all-trans-4-hydroxyretinoic acid

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

cytochrome P450, family 1, subfamily a, polypeptide 1

increases chemical synthesis

CYP1A1 protein results in increased chemical synthesis of 4-hydroxyretinoic acid

NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125

G

cytochrome P450, family 26, subfamily a, polypeptide 1

increases metabolic processing
multiple interactions
increases chemical synthesis
increases expression

CYP26A1 protein results in increased metabolism of 4-hydroxyretinoic acid
[[Ketoconazole results in decreased activity of CYP26A1 protein] which results in decreased metabolism of Tretinoin] which results in decreased chemical synthesis of 4-hydroxyretinoic acid; [[R 115866 results in decreased activity of CYP26A1 protein] which results in decreased metabolism of Tretinoin] which results in decreased chemical synthesis of 4-hydroxyretinoic acid; [CYP26A1 protein results in increased metabolism of Tretinoin] which results in increased chemical synthesis of 4-hydroxyretinoic acid; [Ketoconazole results in decreased activity of CYP26A1 protein] which results in decreased chemical synthesis of 4-hydroxyretinoic acid; [R 115866 results in decreased activity of CYP26A1 protein] which results in decreased chemical synthesis of 4-hydroxyretinoic acid; Ketoconazole inhibits the reaction [CYP26A1 mRNA results in increased chemical synthesis of 4-hydroxyretinoic acid]
CYP26A1 mRNA results in increased chemical synthesis of 4-hydroxyretinoic acid; CYP26A1 protein results in increased chemical synthesis of 4-hydroxyretinoic acid
4-hydroxyretinoic acid results in increased expression of CYP26A1 mRNA

PMID:12091498 PMID:17460545 PMID:25492813

NCBI chr 1:235,471,368...235,475,204
Ensembl chr 1:235,471,298...235,475,204

G

cytochrome P450, family 2, subfamily c, polypeptide 79

increases chemical synthesis

CYP2C8 protein results in increased chemical synthesis of 4-hydroxyretinoic acid

G

cytochrome P450, family 3, subfamily a, polypeptide 2

increases chemical synthesis

CYP3A4 protein results in increased chemical synthesis of 4-hydroxyretinoic acid

NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008

G

mucin 2, oligomeric mucus/gel-forming

increases expression

4-hydroxyretinoic acid results in increased expression of MUC2 mRNA

NCBI chr 1:196,799,494...196,831,740
Ensembl chr 1:196,799,517...196,831,756

G

mucin 5AC, oligomeric mucus/gel-forming

increases expression

4-hydroxyretinoic acid results in increased expression of MUC5AC mRNA

NCBI chr 1:196,864,336...196,896,475
Ensembl chr 1:196,864,336...196,896,475

G

retinoic acid receptor, alpha

increases activity

4-hydroxyretinoic acid results in increased activity of RARA protein

NCBI chr10:83,883,490...83,928,932
Ensembl chr10:83,893,384...83,928,142

G

retinoic acid receptor, beta

increases activity
increases expression

4-hydroxyretinoic acid results in increased activity of RARB protein
4-hydroxyretinoic acid results in increased expression of RARB mRNA

NCBI chr15:8,700,533...9,051,288
Ensembl chr15:8,406,492...9,051,288

G

retinoic acid receptor, gamma

increases activity

4-hydroxyretinoic acid results in increased activity of RARG protein

NCBI chr 7:133,367,833...133,390,301
Ensembl chr 7:133,367,833...133,390,177

beraprost

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

caspase 3

multiple interactions

beraprost inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased cleavage of CASP3 protein]

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

glutamic--pyruvic transaminase

multiple interactions

(2-(4-(4-isopropoxybenzyl)-phenylamino) imidazoline) inhibits the reaction [beraprost inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of GPT protein]]; beraprost inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of GPT protein]

NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494

G

heparin-binding EGF-like growth factor

multiple interactions

beraprost inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of HBEGF mRNA]

NCBI chr18:28,106,284...28,116,167
Ensembl chr18:28,105,760...28,116,441

G

hepatocyte growth factor

decreases expression

beraprost results in decreased expression of HGF mRNA

NCBI chr 4:18,673,736...18,745,582
Ensembl chr 4:18,677,101...18,745,409

G

heme oxygenase 1

multiple interactions

beraprost inhibits the reaction [Hydrochloric Acid results in increased expression of HMOX1 protein]

NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079

G

myeloperoxidase

multiple interactions

beraprost inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of MPO protein]

NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819

G

NFE2 like bZIP transcription factor 2

multiple interactions

beraprost inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of NFE2L2 mRNA]

NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737

G

prostaglandin I2 receptor

multiple interactions

beraprost binds to and results in increased activity of PTGIR protein; Endocannabinoids inhibits the reaction [beraprost binds to and results in increased activity of PTGIR protein]

NCBI chr 1:77,579,596...77,581,979
Ensembl chr 1:77,579,596...77,581,979

G

signal transducer and activator of transcription 3

multiple interactions

beraprost inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased phosphorylation of STAT3 protein]

NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057

G

tumor necrosis factor

multiple interactions

beraprost inhibits the reaction [[Galactosamine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of TNF mRNA]

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

carbocyclic thromboxane A2

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

TNF receptor superfamily member 11B

decreases expression

thromboxane A2, carbocyclic results in decreased expression of TNFRSF11B mRNA

NCBI chr 7:85,566,520...85,594,526
Ensembl chr 7:85,566,520...85,594,538

G

TNF superfamily member 11

increases expression

thromboxane A2, carbocyclic results in increased expression of TNFSF11 mRNA

NCBI chr15:53,673,850...53,705,325
Ensembl chr15:53,673,877...53,705,445

fostriecin

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

Bcl-2 binding component 3

multiple interactions

fostriecin inhibits the reaction [Tetrachlorodibenzodioxin inhibits the reaction [Benzo(a)pyrene results in increased expression of BBC3 protein]]

NCBI chr 1:77,013,281...77,022,509
Ensembl chr 1:77,014,543...77,022,509

G

caspase 3

multiple interactions

fostriecin inhibits the reaction [Tetrachlorodibenzodioxin inhibits the reaction [Benzo(a)pyrene results in increased cleavage of CASP3 protein]]

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

forkhead box O3

multiple interactions

fostriecin inhibits the reaction [Tetrachlorodibenzodioxin inhibits the reaction [Benzo(a)pyrene results in increased phosphorylation of FOXO3 protein]]

NCBI chr20:45,669,708...45,764,606
Ensembl chr20:45,672,995...45,764,561

G

tumor protein p53

multiple interactions

fostriecin promotes the reaction [Tetrachlorodibenzodioxin promotes the reaction [Benzo(a)pyrene results in increased expression of TP53 protein]]

NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524

piericidin A

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

microtubule-associated protein tau

increases response to substance
increases phosphorylation

MAPT protein polymorphism results in increased susceptibility to piericidin A
piericidin A results in increased phosphorylation of MAPT protein polymorphism

NCBI chr10:89,138,644...89,236,137
Ensembl chr10:89,138,627...89,236,129

pravastatin

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily A member 1

multiple interactions
increases expression
decreases expression

[[colestimide co-treated with Pravastatin] results in increased expression of ABCA1 protein] which results in decreased abundance of Cholesterol; [colestimide co-treated with Pravastatin] affects the expression of ABCA1 mRNA; [colestimide co-treated with Pravastatin] affects the expression of ABCA1 protein
cotreatment with pravastatin and colestimide increases expression of abca1 mRNA and protein in rat liver; and decreases expression of abca1 mRNA and protein in rat small intestine
Pravastatin results in decreased expression of ABCA1

CTD
RGD

PMID:17526932 PMID:19461118 PMID:17526932

NCBI chr 5:67,678,267...67,801,162
Ensembl chr 5:67,681,297...67,801,170

G

ATP binding cassette subfamily B member 11

multiple interactions
affects import

Pravastatin inhibits the reaction [ABCB11 protein affects the import of Taurocholic Acid]
ABCB11 protein affects the import of Pravastatin

NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730

G

ATP binding cassette subfamily B member 1A

increases transport

ABCB1 protein results in increased transport of Pravastatin; ABCB1 protein results in increased transport of Pravastatin analog

NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709

G

ATP binding cassette subfamily B member 4

increases expression

Pravastatin results in increased expression of ABCB4 mRNA

NCBI chr 4:25,150,998...25,209,489
Ensembl chr 4:25,151,953...25,209,202

G

ATP binding cassette subfamily C member 2

affects export
increases expression
multiple interactions
affects transport

ABCC2 protein affects the export of Pravastatin
Pravastatin results in increased expression of ABCC2 protein
ABCC2 protein binds to and results in increased uptake of Pravastatin analog; Pravastatin analog inhibits the reaction [ABCC2 protein binds to and results in increased uptake of 5(6)-carboxy-2',7'-dichlorofluorescein]; Pravastatin promotes the reaction [ABCC2 protein results in increased export of 5(6)-carboxy-2',7'-dichlorofluorescein]
ABCC2 protein affects the transport of Pravastatin

PMID:15901800 PMID:15955871 PMID:23562342 PMID:24909372

NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238

G

ATP binding cassette subfamily C member 3

increases expression

Pravastatin results in increased expression of ABCC3 protein

NCBI chr10:79,296,681...79,342,749
Ensembl chr10:79,296,693...79,342,595

G

ATP binding cassette subfamily C member 4

increases transport

ABCC4 protein results in increased transport of Pravastatin

NCBI chr15:95,541,186...95,774,898
Ensembl chr15:95,542,315...95,774,283

G

ATP binding cassette subfamily D member 3

decreases expression

Pravastatin results in decreased expression of ABCD3 mRNA

NCBI chr 2:209,852,087...209,905,763
Ensembl chr 2:209,852,087...209,906,020

G

ATP binding cassette subfamily G member 2

affects export
increases activity

ABCG2 protein affects the export of Pravastatin
Pravastatin results in increased activity of ABCG2 protein

PMID:15901800 PMID:27475308

NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409

G

ATP binding cassette subfamily G member 5

increases expression

Pravastatin results in increased expression of ABCG5 mRNA

NCBI chr 6:9,965,118...9,990,563
Ensembl chr 6:9,965,118...9,990,563

G

ATP binding cassette subfamily G member 8

increases expression

Pravastatin results in increased expression of ABCG8 mRNA

NCBI chr 6:9,945,629...9,964,912
Ensembl chr 6:9,945,629...9,964,912

G

acetyl-Coenzyme A acyltransferase 1B

decreases expression

Pravastatin results in decreased expression of ACAA1B mRNA

NCBI chr 8:118,872,996...118,881,852
Ensembl chr 8:118,872,997...118,881,825

G

acetyl-CoA acyltransferase 2

decreases expression

Pravastatin results in decreased expression of ACAA2 mRNA

NCBI chr18:68,345,136...68,373,246
Ensembl chr18:68,345,012...68,373,249

G

acetyl-CoA acetyltransferase 1

decreases expression

Pravastatin results in decreased expression of ACAT1 mRNA

NCBI chr 8:53,979,813...54,008,861
Ensembl chr 8:53,979,813...54,008,855

G

angiotensin I converting enzyme

multiple interactions

[INS1 protein co-treated with Pravastatin] inhibits the reaction [Streptozocin results in increased expression of ACE protein]

NCBI chr10:90,910,316...90,930,437
Ensembl chr10:90,910,316...90,931,131

G

angiotensin converting enzyme 2

multiple interactions

[INS1 protein co-treated with Pravastatin] inhibits the reaction [Streptozocin results in decreased expression of ACE2 protein]

NCBI chr X:30,293,597...30,340,961
Ensembl chr X:30,293,589...30,340,977

G

acyl-CoA thioesterase 1

increases expression
decreases expression

Pravastatin results in increased expression of ACOT1 mRNA
Pravastatin results in decreased expression of ACOT1 mRNA

NCBI chr 6:103,636,173...103,644,167
Ensembl chr 6:103,636,041...103,644,163

G

acyl-CoA thioesterase 12

decreases expression

Pravastatin results in decreased expression of ACOT12 mRNA

NCBI chr 2:22,986,867...23,027,538
Ensembl chr 2:22,986,626...23,027,536

G

acyl-CoA thioesterase 2

affects expression

Pravastatin affects the expression of ACOT2 mRNA

NCBI chr 6:103,611,738...103,619,404
Ensembl chr 6:103,611,544...103,619,245

G

acyl-CoA thioesterase 3

decreases expression

Pravastatin results in decreased expression of ACOT3 mRNA

NCBI chr 6:103,682,518...103,688,735
Ensembl chr 6:103,682,596...103,688,427
Ensembl chr 6:103,682,596...103,688,427

G

acyl-CoA thioesterase 4

decreases expression

Pravastatin results in decreased expression of ACOT4 mRNA

NCBI chr 6:103,668,699...103,674,037
Ensembl chr 6:103,668,753...103,673,917

G

acyl-CoA oxidase 1

decreases expression

Pravastatin results in decreased expression of ACOX1 mRNA

NCBI chr10:101,406,197...101,431,252
Ensembl chr10:101,406,197...101,431,232

G

acyl-CoA synthetase family member 2

increases expression
decreases expression

Pravastatin results in increased expression of ACSF2 mRNA
Pravastatin results in decreased expression of ACSF2 mRNA

NCBI chr10:79,504,510...79,546,714
Ensembl chr10:79,504,511...79,546,673

G

acyl-CoA synthetase long-chain family member 1

decreases expression

Pravastatin results in decreased expression of ACSL1 mRNA

NCBI chr16:45,755,246...45,821,541
Ensembl chr16:45,755,254...45,821,541

G

actin, alpha 1, skeletal muscle

decreases expression

Pravastatin results in decreased expression of ACTA1 mRNA

NCBI chr19:51,883,709...51,886,735
Ensembl chr19:51,883,715...51,886,742

G

ADAM-like, decysin 1

increases expression

Pravastatin results in increased expression of ADAMDEC1 mRNA

NCBI chr15:42,900,629...42,921,684
Ensembl chr15:42,900,636...42,921,712

G

alcohol dehydrogenase 1C (class I), gamma polypeptide

decreases expression

Pravastatin results in decreased expression of ADH1 mRNA

NCBI chr 2:226,797,303...226,808,892
Ensembl chr 2:226,797,303...226,808,892

G

alcohol dehydrogenase 7 (class IV), mu or sigma polypeptide

decreases expression

Pravastatin results in decreased expression of ADH7 mRNA

NCBI chr 2:226,748,724...226,763,183
Ensembl chr 2:226,741,788...226,763,182

G

angiotensinogen

decreases expression

Pravastatin results in decreased expression of AGT mRNA

NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977

G

allograft inflammatory factor 1

decreases expression

Pravastatin results in decreased expression of AIF1 mRNA

NCBI chr20:3,646,784...3,652,670
Ensembl chr20:3,646,777...3,652,668

G

aldo-keto reductase family 1, member C3

decreases expression

Pravastatin results in decreased expression of AKR1C18 mRNA
Pravastatin results in decreased expression of AKR1C3 mRNA

NCBI chr17:66,110,970...66,127,867
Ensembl chr17:66,110,963...66,127,873

G

AKT serine/threonine kinase 1

multiple interactions
increases phosphorylation

Pravastatin inhibits the reaction [Carboplatin results in increased activity of and results in increased phosphorylation of AKT1 protein]
Pravastatin results in increased phosphorylation of AKT1 protein
[Pravastatin co-treated with olmesartan] results in increased phosphorylation of AKT1 protein; [resveratrol co-treated with Pravastatin] results in increased phosphorylation of AKT1 protein

PMID:17170375 PMID:17188708 PMID:18483861

NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921

G

aldehyde dehydrogenase 1 family, member A1

decreases expression

Pravastatin results in decreased expression of ALDH1A1 mRNA

PMID:16763553 PMID:27225895

NCBI chr 1:218,000,470...218,152,962
Ensembl chr 1:218,042,127...218,152,961

G

aldehyde dehydrogenase 1 family, member A2

multiple interactions
decreases expression

Cholesterol, Dietary inhibits the reaction [Pravastatin results in decreased expression of ALDH1A2 mRNA]

NCBI chr 8:71,877,850...71,957,107
Ensembl chr 8:71,877,850...71,957,107

G

aldehyde dehydrogenase 1 family, member A3

affects expression

Pravastatin affects the expression of ALDH1A3 mRNA

NCBI chr 1:119,982,272...120,017,416
Ensembl chr 1:119,982,277...120,017,436

G

aldolase 1 A retrogene 2

increases expression
decreases expression

Pravastatin results in increased expression of ALDOART2 mRNA
Pravastatin results in decreased expression of ALDOART2 mRNA

NCBI chr 6:72,939,821...72,941,511
Ensembl chr 6:72,939,788...72,941,709

G

adenosine monophosphate deaminase 3

increases expression

Pravastatin results in increased expression of AMPD3 mRNA

NCBI chr 1:164,884,823...164,929,899
Ensembl chr 1:164,885,320...164,929,887

G

angiopoietin-like 3

decreases expression

Pravastatin results in decreased expression of ANGPTL3 mRNA

NCBI chr 5:113,703,007...113,710,044
Ensembl chr 5:113,703,012...113,709,957

G

ankyrin 2

increases expression
decreases expression

Pravastatin results in increased expression of ANK2 mRNA
Pravastatin results in decreased expression of ANK2 mRNA

NCBI chr 2:215,378,028...215,954,015
Ensembl chr 2:215,379,680...215,862,923

G

ankyrin repeat and sterile alpha motif domain containing 6

increases expression
decreases expression

Pravastatin results in increased expression of ANKS6 mRNA
Pravastatin results in decreased expression of ANKS6 mRNA

NCBI chr 5:61,309,183...61,350,596
Ensembl chr 5:61,309,183...61,350,596

G

apolipoprotein A1

increases expression
decreases expression

Pravastatin results in increased expression of APOA1 mRNA
Pravastatin results in decreased expression of APOA1 mRNA

NCBI chr 8:46,527,251...46,529,035
Ensembl chr 8:46,527,144...46,529,035

G

amyloid beta precursor protein

increases expression

Pravastatin results in increased expression of APP

NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561

G

arginase 2

increases expression

Pravastatin results in increased expression of ARG2 mRNA

NCBI chr 6:97,936,002...97,961,379
Ensembl chr 6:97,936,002...97,961,378

G

Rho GTPase activating protein 11A

decreases expression
affects expression

Pravastatin results in decreased expression of ARHGAP11A mRNA
Pravastatin affects the expression of ARHGAP11A mRNA

NCBI chr 3:100,590,865...100,607,146
Ensembl chr 3:100,590,865...100,607,559

G

arrestin domain containing 3

decreases expression

Pravastatin results in decreased expression of ARRDC3 mRNA

NCBI chr 2:11,137,464...11,149,978
Ensembl chr 2:11,137,460...11,149,978

G

ATPase H+/K+ transporting subunit alpha

decreases expression

Pravastatin results in decreased expression of ATP4A mRNA

NCBI chr 1:85,961,607...85,974,972
Ensembl chr 1:85,961,708...85,974,844

G

ATPase H+ transporting V0 subunit D2

increases expression
decreases expression

Pravastatin results in increased expression of ATP6V0D2 mRNA
Pravastatin results in decreased expression of ATP6V0D2 mRNA

NCBI chr 5:33,336,257...33,385,354
Ensembl chr 5:33,336,264...33,385,354

G

axin 2

decreases expression

Pravastatin results in decreased expression of AXIN2 mRNA

NCBI chr10:93,893,830...93,927,042
Ensembl chr10:93,899,245...93,926,231

G

BRCA1 associated RING domain 1

decreases expression
affects expression

Pravastatin results in decreased expression of BARD1 mRNA
Pravastatin affects the expression of BARD1 mRNA

NCBI chr 9:72,616,070...72,694,553
Ensembl chr 9:72,623,155...72,694,265

G

BCL2 associated X, apoptosis regulator

multiple interactions

[LDLR gene mutant form results in increased susceptibility to Pravastatin] which affects the expression of BAX protein

NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368

G

BCL2, apoptosis regulator

multiple interactions

[LDLR gene mutant form results in increased susceptibility to Pravastatin] which affects the expression of BCL2 protein

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

basic helix-loop-helix family, member a15

decreases expression

Pravastatin results in decreased expression of BHLHA15 mRNA

NCBI chr12:10,420,465...10,424,641
Ensembl chr12:10,420,467...10,424,713

G

basic helix-loop-helix ARNT like 2

affects expression
increases expression

Pravastatin affects the expression of BMAL2 mRNA
Pravastatin results in increased expression of BMAL2 mRNA

NCBI chr 4:179,699,432...179,747,710
Ensembl chr 4:179,699,502...179,746,949

G

BMP-binding endothelial regulator

affects expression
increases expression

Pravastatin affects the expression of BMPER mRNA
Pravastatin results in increased expression of BMPER mRNA

NCBI chr 8:21,732,225...21,977,261
Ensembl chr 8:21,732,225...21,977,256

G

BUB1 mitotic checkpoint serine/threonine kinase B

affects expression
decreases expression

Pravastatin affects the expression of BUB1B mRNA
Pravastatin results in decreased expression of BUB1B mRNA

NCBI chr 3:105,563,089...105,615,547
Ensembl chr 3:105,563,138...105,615,547

G

complement C1q B chain

decreases expression

Pravastatin results in decreased expression of C1QB mRNA

NCBI chr 5:149,118,843...149,124,394
Ensembl chr 5:149,118,846...149,124,407

G

complement C1q C chain

decreases expression

Pravastatin results in decreased expression of C1QC mRNA

NCBI chr 5:149,127,412...149,130,757
Ensembl chr 5:149,127,415...149,131,017

G

complement C5a receptor 1

decreases expression

Pravastatin results in decreased expression of C5AR1 mRNA

NCBI chr 1:76,948,622...76,959,826

G

caspase 3

multiple interactions
increases cleavage

[LDLR gene mutant form results in increased susceptibility to Pravastatin] which results in increased cleavage of CASP3 protein; Pravastatin inhibits the reaction [Carboplatin results in increased expression of CASP3 protein]
Pravastatin results in increased cleavage of CASP3 protein
Pravastatin inhibits the reaction [Carboplatin results in increased expression of CASP3 protein]; Pravastatin inhibits the reaction [Cisplatin results in increased expression of CASP3 protein]

PMID:18483861 PMID:20368269 PMID:26875785

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

caspase 9

multiple interactions

Pravastatin inhibits the reaction [Carboplatin results in increased expression of CASP9 protein]

NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626

G

catalase

increases activity

Pravastatin results in increased activity of CAT protein

NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478

G

C-C motif chemokine ligand 12

decreases expression

Pravastatin results in decreased expression of CCL12 mRNA

NCBI chr10:67,070,230...67,071,780
Ensembl chr10:67,070,230...67,071,780

G

C-C motif chemokine ligand 2

multiple interactions

Pravastatin inhibits the reaction [LEP gene mutant form results in increased expression of CCL2 mRNA]; Pravastatin inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 mRNA]
Pravastatin inhibits the reaction [lopinavir-ritonavir drug combination results in increased secretion of CCL2 protein]; Pravastatin inhibits the reaction [Ritonavir results in increased secretion of CCL2 protein]

PMID:18323514 PMID:20884875

NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226

G

C-C motif chemokine ligand 9

decreases expression

Pravastatin results in decreased expression of CCL6 mRNA

NCBI chr10:68,366,486...68,371,408
Ensembl chr10:68,366,487...68,371,369

G

CD209d molecule

decreases expression

Pravastatin results in decreased expression of CD209 mRNA

NCBI chr12:1,891,109...1,897,559
Ensembl chr12:1,891,113...1,901,171

G

Cd28 molecule

decreases expression
affects expression

Pravastatin results in decreased expression of CD28 mRNA
Pravastatin affects the expression of CD28 mRNA

NCBI chr 9:62,166,324...62,194,674
Ensembl chr 9:62,166,192...62,194,685

G

CD40 molecule

affects expression

Pravastatin affects the expression of CD40 mRNA

NCBI chr 3:153,790,372...153,805,279
Ensembl chr 3:153,790,449...153,805,534

G

Cd7 molecule

decreases expression

Pravastatin results in decreased expression of CD7 mRNA

NCBI chr10:106,304,046...106,306,963
Ensembl chr10:106,304,056...106,306,967

G

cell division cycle 27

affects expression
increases expression

Pravastatin affects the expression of CDC27 mRNA
Pravastatin results in increased expression of CDC27 mRNA

NCBI chr10:89,400,720...89,449,816
Ensembl chr10:89,400,940...89,449,736

G

cell division cycle 6

decreases expression
affects expression

Pravastatin results in decreased expression of CDC6 mRNA
Pravastatin affects the expression of CDC6 mRNA

NCBI chr10:83,864,189...83,878,011
Ensembl chr10:83,864,638...83,878,011

G

cell division cycle associated 7 like

affects expression
decreases expression

Pravastatin affects the expression of CDCA7L mRNA
Pravastatin results in decreased expression of CDCA7L mRNA

NCBI chr 6:138,793,953...138,839,889
Ensembl chr 6:138,794,228...138,839,888

G

cadherin-related family member 5

decreases expression
increases expression

Pravastatin results in decreased expression of CDHR5 mRNA
Pravastatin results in increased expression of CDHR5 mRNA

NCBI chr 1:196,373,110...196,381,609
Ensembl chr 1:196,373,112...196,381,543

G

cyclin-dependent kinase inhibitor 1A

multiple interactions

Pravastatin inhibits the reaction [Benzo(a)pyrene results in decreased degradation of CDKN1A protein]; Pravastatin inhibits the reaction [Fluorouracil results in decreased degradation of CDKN1A protein]

NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585

G

CDP-diacylglycerol synthase 1

increases expression

Pravastatin results in increased expression of CDS1 mRNA

NCBI chr14:7,820,328...7,882,943
Ensembl chr14:7,820,351...7,882,681

G

CCAAT/enhancer binding protein delta

increases expression

Pravastatin results in increased expression of CEBPD mRNA

NCBI chr11:84,764,670...84,765,808
Ensembl chr11:84,764,565...84,765,829

G

ceramide synthase 6

decreases expression

Pravastatin results in decreased expression of CERS6 mRNA

NCBI chr 3:53,630,637...53,879,692
Ensembl chr 3:53,630,959...53,876,848

G

carboxylesterase-like 1

decreases expression

Pravastatin results in decreased expression of CESL1 mRNA

NCBI chr19:22,670,709...23,006,329
Ensembl chr19:22,670,712...22,712,608

G

cilia and flagella associated protein 96

increases expression

Pravastatin results in increased expression of CFAP96 mRNA

NCBI chr16:46,291,075...46,315,616
Ensembl chr16:46,291,311...46,315,625

G

cellular inhibitor of PP2A

decreases expression

Pravastatin results in decreased expression of CIP2A mRNA

NCBI chr11:51,792,143...51,823,016
Ensembl chr11:51,795,024...51,822,938

G

Cbp/p300-interacting transactivator with Glu/Asp-rich carboxy-terminal domain 1

decreases expression
increases expression

Pravastatin results in decreased expression of CITED1 mRNA
Pravastatin results in increased expression of CITED1 mRNA

NCBI chr X:67,350,376...67,355,072
Ensembl chr X:67,350,373...67,355,162

G

chloride voltage-gated channel 6

increases expression

Pravastatin results in increased expression of CLCN6 mRNA

NCBI chr 5:158,434,299...158,465,174
Ensembl chr 5:158,434,299...158,465,059

G

C-type lectin domain family 4, member F

decreases expression

Pravastatin results in decreased expression of CLEC4F mRNA

NCBI chr 4:116,129,023...116,138,744
Ensembl chr 4:116,129,023...116,138,775

G

calsyntenin 3

decreases expression
affects expression

Pravastatin results in decreased expression of CLSTN3 mRNA
Pravastatin affects the expression of CLSTN3 mRNA

NCBI chr 4:157,331,494...157,364,769
Ensembl chr 4:157,331,494...157,364,769

G

calponin 1

decreases expression

Pravastatin results in decreased expression of CNN1 mRNA

NCBI chr 8:20,632,434...20,641,097
Ensembl chr 8:20,632,338...20,641,098

G

carnitine palmitoyltransferase 1B

decreases expression
affects expression

Pravastatin results in decreased expression of CPT1B mRNA
Pravastatin affects the expression of CPT1B mRNA

NCBI chr 7:120,491,354...120,500,833
Ensembl chr 7:120,491,354...120,500,404

G

carnitine palmitoyltransferase 2

decreases expression

Pravastatin results in decreased expression of CPT2 mRNA

NCBI chr 5:122,664,677...122,682,126
Ensembl chr 5:122,664,677...122,682,095

G

carnitine O-acetyltransferase

increases expression
affects expression

Pravastatin results in increased expression of CRAT mRNA
Pravastatin affects the expression of CRAT mRNA

NCBI chr 3:13,675,684...13,689,282
Ensembl chr 3:13,675,684...13,689,255

G

cAMP responsive element binding protein 3-like 3

decreases expression
affects expression

Pravastatin results in decreased expression of CREB3L3 mRNA
Pravastatin affects the expression of CREB3L3 mRNA

NCBI chr 7:8,622,614...8,631,053
Ensembl chr 7:8,622,614...8,631,048

G

C-reactive protein

decreases expression
increases expression

Pravastatin results in decreased expression of CRP mRNA
Pravastatin results in increased expression of CRP mRNA

NCBI chr13:85,135,384...85,175,178
Ensembl chr13:85,124,977...85,175,178

G

cysteine sulfinic acid decarboxylase

decreases expression

Pravastatin results in decreased expression of CSAD mRNA

NCBI chr 7:133,308,571...133,337,914
Ensembl chr 7:133,308,574...133,337,615

G

colony stimulating factor 1 receptor

decreases expression

Pravastatin results in decreased expression of CSF1R mRNA

NCBI chr18:54,546,673...54,590,418
Ensembl chr18:54,546,659...54,590,415

G

CUB and Sushi multiple domains 1

decreases expression

Pravastatin results in decreased expression of CSMD1 mRNA

NCBI chr16:72,218,189...73,818,380
Ensembl chr16:72,218,503...73,817,614

G

catenin beta 1

affects localization
multiple interactions

Pravastatin affects the localization of CTNNB1 protein
[resveratrol co-treated with Pravastatin] affects the localization of CTNNB1 protein

NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111

G

C-X-C motif chemokine ligand 2

affects expression
increases expression

Pravastatin affects the expression of CXCL2 mRNA
Pravastatin results in increased expression of CXCL2 mRNA

NCBI chr14:17,181,030...17,183,075
Ensembl chr14:17,181,062...17,183,075

G

cytochrome b-245 alpha chain

decreases expression

Pravastatin results in decreased expression of CYBA protein

NCBI chr19:50,487,598...50,495,669
Ensembl chr19:50,487,597...50,495,721

G

cytochrome c, somatic

multiple interactions

Pravastatin inhibits the reaction [Carboplatin results in increased expression of CYCS protein]

NCBI chr 4:79,651,894...79,653,994
Ensembl chr 4:79,651,378...79,654,054
Ensembl chr18:79,651,378...79,654,054

G

cytochrome P450, family 1, subfamily a, polypeptide 2

decreases expression

Pravastatin results in decreased expression of CYP1A2 mRNA

NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312

G

cytochrome P450, family 1, subfamily b, polypeptide 1

affects expression
increases expression

Pravastatin affects the expression of CYP1B1 mRNA
Pravastatin results in increased expression of CYP1B1 mRNA

NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917

G

cytochrome P450, family 2, subfamily b, polypeptide 21

decreases expression

Pravastatin results in decreased expression of CYP2B21 mRNA

NCBI chr 1:81,886,097...81,915,066
Ensembl chr 1:81,886,098...81,915,066

G

cytochrome P450, family 2, subfamily b, polypeptide 3

affects expression

Pravastatin affects the expression of CYP2B10 mRNA

NCBI chr 1:81,652,762...81,732,153
Ensembl chr 1:81,652,787...81,732,143

G

cytochrome P450, family 2, subfamily d, polypeptide 3

decreases expression

Pravastatin results in decreased expression of CYP2D3 mRNA

NCBI chr 7:113,917,711...113,922,068
Ensembl chr 7:113,908,947...113,922,084

G

cytochrome P450, family 2, subfamily j, polypeptide 4

decreases expression

Pravastatin results in decreased expression of CYP2J4 mRNA

NCBI chr 5:111,179,981...111,207,490
Ensembl chr 5:111,178,703...111,244,794

G

cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1

decreases expression

Pravastatin results in decreased expression of CYP3A23-3A1 mRNA

NCBI chr12:9,256,159...9,285,020
Ensembl chr12:9,254,475...9,285,030
Ensembl chr12:9,254,475...9,285,030

G

cytochrome P450, family 4, subfamily a, polypeptide 1

decreases expression

Pravastatin results in decreased expression of CYP4A1 mRNA

NCBI chr 5:129,123,323...129,137,464
Ensembl chr 5:129,123,336...129,137,464

G

cytochrome P450, family 4, subfamily a, polypeptide 2

affects expression

Pravastatin affects the expression of CYP4A2 mRNA

NCBI chr 5:128,922,355...128,934,188
Ensembl chr 5:128,923,615...128,934,165

G

cytochrome P450, family 4, subfamily a, polypeptide 3

decreases expression

Pravastatin results in decreased expression of CYP4A3 mRNA

NCBI chr 5:129,097,571...129,115,488
Ensembl chr 5:129,097,926...129,115,463

G

cytochrome P450, family 51

increases expression

Pravastatin results in increased expression of CYP51 mRNA

NCBI chr 4:30,036,956...30,055,410
Ensembl chr 4:30,036,865...30,055,410
Ensembl chr 6:30,036,865...30,055,410

G

2,4-dienoyl-CoA reductase 1

decreases expression

Pravastatin results in decreased expression of DECR1 mRNA

NCBI chr 5:29,411,172...29,439,054
Ensembl chr 5:29,411,172...29,439,018

G

DEP domain containing 1B

decreases expression
affects expression

Pravastatin results in decreased expression of DEPDC1B mRNA
Pravastatin affects the expression of DEPDC1B mRNA

NCBI chr 2:39,891,163...39,963,779
Ensembl chr 2:39,891,481...39,963,779

G

derlin 3

decreases expression

Pravastatin results in decreased expression of DERL3 mRNA

NCBI chr20:12,754,490...12,768,454
Ensembl chr20:12,763,543...12,767,027

G

iodothyronine deiodinase 3

decreases expression

Pravastatin results in decreased expression of DIO3 mRNA

NCBI chr 6:129,285,747...129,287,608
Ensembl chr 6:129,285,749...129,286,660

G

DLG associated protein 1

increases expression

Pravastatin results in increased expression of DLGAP1 mRNA

NCBI chr 9:109,857,500...110,726,817
Ensembl chr 9:110,167,448...110,726,817

G

DnaJ heat shock protein family (Hsp40) member A1

affects farnesylation

Pravastatin affects the farnesylation of DNAJA1 protein

NCBI chr 5:55,842,414...55,853,326
Ensembl chr 5:55,842,426...55,853,967

G

deoxyribonuclease 2 beta

increases expression
decreases expression

Pravastatin results in increased expression of DNASE2B mRNA
Pravastatin results in decreased expression of DNASE2B mRNA

NCBI chr 2:235,470,915...235,515,211
Ensembl chr 2:235,470,919...235,486,295

G

dihydropyrimidinase-like 2

increases expression

Pravastatin results in increased expression of DPYSL2 mRNA

NCBI chr15:41,005,551...41,111,724
Ensembl chr15:41,005,551...41,111,829

G

denticleless E3 ubiquitin protein ligase homolog

decreases expression
affects expression

Pravastatin results in decreased expression of DTL mRNA
Pravastatin affects the expression of DTL mRNA

NCBI chr13:103,115,810...103,155,029
Ensembl chr13:103,117,186...103,154,890

G

enoyl-CoA hydratase 1

decreases expression

Pravastatin results in decreased expression of ECH1 mRNA

NCBI chr 1:84,114,494...84,120,788
Ensembl chr 1:84,112,751...84,120,795

G

endothelin 1

decreases expression

Pravastatin results in decreased expression of EDN1 protein
Pravastatin results in decreased expression of EDN1 mRNA; Pravastatin results in decreased expression of EDN1 protein

PMID:12105140 PMID:19812503

NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885

G

EF hand domain family, member B

increases expression

Pravastatin results in increased expression of EFHB mRNA

NCBI chr 9:6,372,191...6,441,678
Ensembl chr 9:6,372,194...6,441,919

G

enoyl-CoA hydratase and 3-hydroxyacyl CoA dehydrogenase

decreases expression

Pravastatin results in decreased expression of EHHADH mRNA

NCBI chr11:79,241,927...79,275,173
Ensembl chr11:79,241,938...79,275,188

G

ectonucleotide pyrophosphatase/phosphodiesterase family member 5

affects expression
decreases expression

Pravastatin affects the expression of ENPP5 mRNA
Pravastatin results in decreased expression of ENPP5 mRNA

NCBI chr 9:16,910,187...16,917,633
Ensembl chr 9:16,910,831...16,917,480

G

ectonucleoside triphosphate diphosphohydrolase 2

decreases expression
increases expression

Pravastatin results in decreased expression of ENTPD2 mRNA
Pravastatin results in increased expression of ENTPD2 mRNA

NCBI chr 3:8,213,575...8,219,094
Ensembl chr 3:8,213,663...8,226,866

G

epoxide hydrolase 2

decreases expression

Pravastatin results in decreased expression of EPHX2 mRNA

NCBI chr15:40,289,901...40,327,632
Ensembl chr15:40,289,902...40,327,615

G

epoxide hydrolase 4

increases expression
affects expression

Pravastatin results in increased expression of EPHX4 mRNA
Pravastatin affects the expression of EPHX4 mRNA

NCBI chr14:2,343,376...2,372,680
Ensembl chr14:2,340,248...2,373,022

G

ecotropic viral integration site 2A

decreases expression

Pravastatin results in decreased expression of EVI2A mRNA

NCBI chr10:64,485,760...64,489,660
Ensembl chr10:64,485,200...64,489,843

G

coagulation factor XIII A1 chain

decreases expression

Pravastatin results in decreased expression of F13A1 mRNA

NCBI chr17:27,815,723...27,992,494
Ensembl chr17:27,815,702...27,992,700

G

fatty acid binding protein 1

decreases expression

Pravastatin results in decreased expression of FABP1 mRNA

NCBI chr 4:103,191,015...103,194,791
Ensembl chr 4:103,191,006...103,194,788

G

fatty acid binding protein 2

increases expression
decreases expression

Pravastatin results in increased expression of FABP2 mRNA
Pravastatin results in decreased expression of FABP2 mRNA

NCBI chr 2:211,040,032...211,044,089
Ensembl chr 2:211,040,032...211,044,089

G

fatty acid binding protein 5

increases expression

Pravastatin results in increased expression of FABP5 mRNA

NCBI chr 2:91,765,056...91,768,716
Ensembl chr 2:91,765,056...91,853,773

G

fatty acyl CoA reductase 1

increases expression

Pravastatin results in increased expression of FAR1 mRNA

NCBI chr 1:167,644,622...167,705,868
Ensembl chr 1:167,644,677...167,705,730

G

fibrillin 1

increases expression

Pravastatin results in increased expression of FBN1 mRNA

NCBI chr 3:112,554,257...112,750,835
Ensembl chr 3:112,554,925...112,750,889

G

fructose-bisphosphatase 2

affects expression

Pravastatin affects the expression of FBP2 mRNA

NCBI chr17:2,236,088...2,253,702
Ensembl chr17:2,236,336...2,253,698

G

farnesyl diphosphate farnesyl transferase 1

affects activity

Pravastatin affects the activity of FDFT1 protein

NCBI chr15:37,412,143...37,440,198
Ensembl chr15:37,412,146...37,440,287

G

FYVE, RhoGEF and PH domain containing 2

decreases expression

Pravastatin results in decreased expression of FGD2 mRNA

NCBI chr20:7,424,795...7,441,603
Ensembl chr20:7,424,790...7,441,603

G

fibroblast growth factor 13

affects expression
increases expression

Pravastatin affects the expression of FGF13 mRNA
Pravastatin results in increased expression of FGF13 mRNA

NCBI chr X:137,276,498...137,800,056
Ensembl chr X:137,276,511...137,800,391

G

flagellum associated containing coiled-coil domains 1

increases expression

Pravastatin results in increased expression of FLACC1 mRNA

NCBI chr 9:60,315,581...60,343,692
Ensembl chr 9:60,315,582...60,343,648

G

flotillin 1

decreases expression

Pravastatin results in decreased expression of FLOT1 protein

NCBI chr20:2,917,864...2,927,993
Ensembl chr20:2,917,137...2,927,978

G

folate receptor beta

decreases expression

Pravastatin results in decreased expression of FOLR2 mRNA

NCBI chr 1:156,200,044...156,218,380
Ensembl chr 1:156,200,060...156,205,724

G

forkhead box O1

decreases phosphorylation

Pravastatin results in decreased phosphorylation of FOXO1 protein

NCBI chr 2:136,312,168...136,390,603
Ensembl chr 2:136,312,168...136,387,790

G

glucokinase

decreases expression

Pravastatin results in decreased expression of GCK mRNA

NCBI chr14:80,785,060...80,829,842
Ensembl chr14:80,785,060...80,826,995

G

glutamate-cysteine ligase, catalytic subunit

increases expression
decreases expression

Pravastatin results in increased expression of GCLC mRNA
Pravastatin results in decreased expression of GCLC mRNA

NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544

G

glucosaminyl (N-acetyl) transferase 2

increases expression
decreases expression

Pravastatin results in increased expression of GCNT2 mRNA
Pravastatin results in decreased expression of GCNT2 mRNA

NCBI chr17:23,796,859...23,901,625
Ensembl chr17:23,796,859...23,901,611

G

galactosidase, beta 1

multiple interactions

Pravastatin inhibits the reaction [lopinavir-ritonavir drug combination results in increased activity of GLB1 protein]; Pravastatin inhibits the reaction [Ritonavir results in increased activity of GLB1 protein]

NCBI chr 8:114,085,508...114,158,127
Ensembl chr 8:114,085,508...114,158,127

G

glycine decarboxylase

decreases expression

Pravastatin results in decreased expression of GLDC mRNA

NCBI chr 1:227,883,249...227,962,119
Ensembl chr 1:227,883,249...227,962,097

G

glutaminase 2

decreases expression

Pravastatin results in decreased expression of GLS2 mRNA

NCBI chr 7:617,252...633,424
Ensembl chr 7:617,288...633,426

G

G protein-coupled receptor 85

increases expression

Pravastatin results in increased expression of GPR85 mRNA

NCBI chr 4:42,100,138...42,109,584
Ensembl chr 4:42,102,941...42,109,566

G

glutathione S-transferase kappa 1

decreases expression

Pravastatin results in decreased expression of GSTK1 mRNA

NCBI chr 4:71,118,979...71,123,298
Ensembl chr 4:71,118,896...71,123,292

G

hydroxyacyl-CoA dehydrogenase

decreases expression

Pravastatin results in decreased expression of HADH mRNA

NCBI chr 2:219,787,935...219,830,335
Ensembl chr 2:219,787,927...219,830,353

G

hydroxyacyl-CoA dehydrogenase trifunctional multienzyme complex subunit alpha

decreases expression

Pravastatin results in decreased expression of HADHA mRNA

NCBI chr 6:26,187,969...26,227,605
Ensembl chr 6:26,187,956...26,227,869

G

hydroxyacyl-CoA dehydrogenase trifunctional multienzyme complex subunit beta

decreases expression

Pravastatin results in decreased expression of HADHB mRNA

NCBI chr 6:26,153,572...26,187,668
Ensembl chr 6:26,153,578...26,184,869

G

hepcidin antimicrobial peptide

increases expression

Pravastatin results in increased expression of HAMP mRNA

NCBI chr 1:86,170,926...86,172,865
Ensembl chr 1:86,170,901...86,172,891

G

HCLS1 associated protein X-1

multiple interactions

Pravastatin inhibits the reaction [Carboplatin results in decreased expression of HAX1 protein]

NCBI chr 2:175,434,242...175,437,926
Ensembl chr 2:175,434,238...175,437,714

G

3-hydroxy-3-methylglutaryl-CoA reductase

decreases response to substance
increases expression
decreases activity
affects expression

HMGCR gene SNP results in decreased susceptibility to Pravastatin
Pravastatin results in increased expression of HMGCR mRNA
Pravastatin results in decreased activity of HMGCR protein
Pravastatin affects the expression of HMGCR mRNA

PMID:8517861 PMID:8593127 PMID:15199031 PMID:27225895 PMID:29969672

NCBI chr 2:27,997,523...28,018,983
Ensembl chr 2:27,997,525...28,019,703

G

3-hydroxy-3-methylglutaryl-CoA synthase 1

increases expression

Pravastatin results in increased expression of HMGCS1 mRNA

NCBI chr 2:51,649,368...51,667,100
Ensembl chr 2:51,649,497...51,667,100

G

heme oxygenase 1

multiple interactions
increases expression

[[Pravastatin co-treated with pirinixic acid] co-treated with [RXRA protein co-treated with PPARA protein]] results in increased expression of HMOX1 mRNA; [Pravastatin co-treated with [RXRA protein co-treated with PPARA protein]] results in increased expression of HMOX1 mRNA; [Pravastatin co-treated with pirinixic acid] results in increased expression of HMOX1 mRNA; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [Pravastatin results in increased expression of HMOX1 protein]; Pravastatin promotes the reaction [PPARA protein binds to HMOX1 promoter]

NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079

G

HOP homeobox

decreases expression

Pravastatin results in decreased expression of HOPX mRNA

NCBI chr14:31,055,912...31,082,909
Ensembl chr14:31,075,148...31,082,909

G

histidine-rich glycoprotein

decreases expression

Pravastatin results in decreased expression of HRG mRNA

NCBI chr11:78,054,488...78,069,402
Ensembl chr11:78,054,498...78,069,389

G

hydroxysteroid (17-beta) dehydrogenase 7

increases expression

Pravastatin results in increased expression of HSD17B7 mRNA

NCBI chr13:82,170,079...82,190,018
Ensembl chr13:82,173,179...82,190,017

G

hydroxysteroid dehydrogenase like 2

decreases expression
increases expression

Pravastatin results in decreased expression of HSDL2 mRNA
Pravastatin results in increased expression of HSDL2 mRNA

NCBI chr 5:74,443,933...74,479,104
Ensembl chr 5:74,443,872...74,479,839

G

isopentenyl-diphosphate delta isomerase 1

increases expression

Pravastatin results in increased expression of IDI1 mRNA

NCBI chr17:61,629,592...61,637,357
Ensembl chr17:61,629,594...61,637,357

G

interferon beta 1

multiple interactions

Pravastatin inhibits the reaction [Lipopolysaccharides results in increased expression of IFNB1 mRNA]; Pravastatin inhibits the reaction [Palmitic Acid results in increased expression of IFNB1 mRNA]; Pravastatin inhibits the reaction [Poly I-C results in increased expression of IFNB1 mRNA]

NCBI chr 5:103,020,758...103,021,595
Ensembl chr 5:103,020,969...103,021,523

G

interleukin 1 beta

decreases expression
increases expression

Pravastatin results in decreased expression of IL1B mRNA
Pravastatin results in increased expression of IL1B mRNA

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 6

multiple interactions
decreases expression

Pravastatin inhibits the reaction [LEP gene mutant form results in increased expression of IL6 mRNA]; Pravastatin inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]; Pravastatin inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein]; Pravastatin inhibits the reaction [Palmitic Acid results in increased expression of IL6 mRNA]; Pravastatin inhibits the reaction [Poly I-C results in increased expression of IL6 mRNA]; Pravastatin promotes the reaction [[Lipopolysaccharides co-treated with TNF] results in increased expression of IL6 protein]
Pravastatin inhibits the reaction [lopinavir-ritonavir drug combination results in increased secretion of IL6 protein]; Pravastatin inhibits the reaction [Ritonavir results in increased secretion of IL6 protein]
Pravastatin results in decreased expression of IL6 protein

PMID:17729120 PMID:18323514 PMID:19330073 PMID:20884875

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

insulin 1

multiple interactions
increases response to substance

[INS1 protein co-treated with Pravastatin] inhibits the reaction [Streptozocin results in decreased expression of ACE2 protein]; [INS1 protein co-treated with Pravastatin] inhibits the reaction [Streptozocin results in increased expression of ACE protein]
[LDLR gene mutant form results in increased susceptibility to Pravastatin] inhibits the reaction [Glucose results in increased secretion of INS1 protein]; [LDLR gene mutant form results in increased susceptibility to Pravastatin] which results in decreased expression of INS1 protein
[LDLR gene mutant form results in increased susceptibility to Pravastatin] which results in increased susceptibility to INS1 protein

PMID:26875785 PMID:29682576

NCBI chr 1:251,244,973...251,245,540
Ensembl chr 1:251,244,973...251,245,536

G

interferon regulatory factor 3

multiple interactions

Pravastatin inhibits the reaction [Palmitic Acid results in increased phosphorylation of IRF3 protein]

NCBI chr 1:95,479,966...95,484,926
Ensembl chr 1:95,479,821...95,484,935

G

integrin subunit alpha 2

multiple interactions

geranylgeraniol inhibits the reaction [Pravastatin results in increased expression of [ITGA2 protein binds to ITGB1 protein]]; Mevalonic Acid inhibits the reaction [Pravastatin results in increased expression of [ITGA2 protein binds to ITGB1 protein]]; Pravastatin results in increased expression of [ITGA2 protein binds to ITGB1 protein]

NCBI chr 2:46,520,345...46,621,487
Ensembl chr 2:46,523,948...46,621,481

G

integrin subunit beta 1

multiple interactions

geranylgeraniol inhibits the reaction [Pravastatin results in increased expression of [ITGA2 protein binds to ITGB1 protein]]; Mevalonic Acid inhibits the reaction [Pravastatin results in increased expression of [ITGA2 protein binds to ITGB1 protein]]; Pravastatin results in increased expression of [ITGA2 protein binds to ITGB1 protein]

NCBI chr19:56,705,123...56,753,199
Ensembl chr19:56,705,171...56,753,195

G

integrin subunit beta 6

affects expression

Pravastatin affects the expression of ITGB6 mRNA

NCBI chr 3:45,046,295...45,170,532
Ensembl chr 3:45,048,044...45,121,671

G

potassium voltage-gated channel, modifier subfamily S, member 3

increases expression

Pravastatin results in increased expression of KCNS3 mRNA

NCBI chr 6:33,808,314...33,865,018
Ensembl chr 6:33,808,216...33,865,125

G

potassium channel tetramerization domain containing 12

decreases expression

Pravastatin results in decreased expression of KCTD12 mRNA

NCBI chr15:79,800,078...79,806,017
Ensembl chr15:79,801,191...79,806,282

G

kinesin family member 20A

affects expression
decreases expression

Pravastatin affects the expression of KIF20A mRNA
Pravastatin results in decreased expression of KIF20A mRNA

NCBI chr18:26,230,294...26,238,780
Ensembl chr18:26,230,230...26,238,780

G

kinesin family member 20B

affects expression
decreases expression

Pravastatin affects the expression of KIF20B mRNA
Pravastatin results in decreased expression of KIF20B mRNA

NCBI chr 1:232,428,293...232,483,798
Ensembl chr 1:232,428,371...232,483,787

G

kinesin family member 23

affects expression
decreases expression

Pravastatin affects the expression of KIF23 mRNA
Pravastatin results in decreased expression of KIF23 mRNA

NCBI chr 8:62,397,908...62,425,162
Ensembl chr 8:62,397,948...62,425,072

G

KIT ligand

increases expression
affects expression

Pravastatin results in increased expression of KITLG mRNA
Pravastatin affects the expression of KITL mRNA

NCBI chr 7:34,896,075...34,977,215
Ensembl chr 7:34,896,053...34,977,214

G

klotho beta

decreases expression

Pravastatin results in decreased expression of KLB mRNA

NCBI chr14:42,899,050...42,950,788
Ensembl chr14:42,899,510...42,950,799

G

keratin 23

decreases expression

Pravastatin results in decreased expression of KRT23 mRNA

NCBI chr10:84,434,445...84,450,773
Ensembl chr10:84,434,380...84,450,983

G

low density lipoprotein receptor

increases activity
increases response to substance
multiple interactions

Pravastatin results in increased activity of LDLR protein
[LDLR gene mutant form results in increased susceptibility to Pravastatin] which results in increased susceptibility to INS1 protein; LDLR gene mutant form results in increased susceptibility to Pravastatin
[LDLR gene mutant form results in increased susceptibility to Pravastatin] inhibits the reaction [Glucose results in increased secretion of INS1 protein]; [LDLR gene mutant form results in increased susceptibility to Pravastatin] which affects the expression of BAX protein; [LDLR gene mutant form results in increased susceptibility to Pravastatin] which affects the expression of BCL2 protein; [LDLR gene mutant form results in increased susceptibility to Pravastatin] which results in decreased expression of INS1 protein; [LDLR gene mutant form results in increased susceptibility to Pravastatin] which results in decreased expression of SNAP25 protein; [LDLR gene mutant form results in increased susceptibility to Pravastatin] which results in decreased expression of STX1A protein; [LDLR gene mutant form results in increased susceptibility to Pravastatin] which results in decreased expression of VAMP2 protein; [LDLR gene mutant form results in increased susceptibility to Pravastatin] which results in increased cleavage of CASP3 protein

PMID:8593127 PMID:26875785

NCBI chr 8:20,270,020...20,292,981
Ensembl chr 8:20,270,041...20,294,580

G

leptin

multiple interactions

Pravastatin inhibits the reaction [LEP gene mutant form results in increased expression of CCL2 mRNA]; Pravastatin inhibits the reaction [LEP gene mutant form results in increased expression of IL6 mRNA]; Pravastatin inhibits the reaction [LEP gene mutant form results in increased expression of TNF mRNA]

NCBI chr 4:57,661,127...57,675,262
Ensembl chr 4:57,661,131...57,675,262

G

galectin 4

increases expression
decreases expression

Pravastatin results in increased expression of LGALS4 mRNA
Pravastatin results in decreased expression of LGALS4 mRNA

NCBI chr 1:84,124,766...84,132,481
Ensembl chr 1:84,124,764...84,132,481

G

leucine-rich repeat LGI family, member 2

increases expression

Pravastatin results in increased expression of LGI2 mRNA

NCBI chr14:58,415,965...58,443,450
Ensembl chr14:58,415,965...58,443,407

G

lamin A/C

increases expression

Pravastatin results in increased expression of LMNA protein

NCBI chr 2:173,939,751...173,960,423
Ensembl chr 2:173,939,751...173,960,423

G

lipoprotein lipase

decreases expression

Pravastatin results in decreased expression of LPL mRNA

NCBI chr16:20,830,055...20,853,855
Ensembl chr16:20,829,465...20,855,249

G

leucine rich melanocyte differentiation associated

decreases expression

Pravastatin results in decreased expression of LRMDA mRNA

NCBI chr15:1,223,098...2,284,764
Ensembl chr15:1,225,710...2,284,749

G

lanosterol synthase

increases expression

Pravastatin results in increased expression of LSS mRNA

NCBI chr20:12,091,138...12,118,858
Ensembl chr20:12,092,774...12,118,762

G

latent transforming growth factor beta binding protein 2

increases expression

Pravastatin results in increased expression of LTBP2 mRNA

NCBI chr 6:104,429,947...104,530,498
Ensembl chr 6:104,429,947...104,526,208

G

lymphocyte antigen 86

decreases expression

Pravastatin results in decreased expression of LY86 mRNA

NCBI chr17:27,415,807...27,499,695
Ensembl chr17:27,415,830...27,487,260

G

microtubule-associated protein tau

affects expression
decreases expression

Pravastatin affects the expression of MAPT
Pravastatin results in decreased expression of MAPT mRNA

PMID:19461118 PMID:27225895

NCBI chr10:89,138,644...89,236,137
Ensembl chr10:89,138,627...89,236,129

G

microtubule associated serine/threonine kinase-like

affects expression
decreases expression

Pravastatin affects the expression of MASTL mRNA
Pravastatin results in decreased expression of MASTL mRNA

NCBI chr17:85,250,512...85,287,479
Ensembl chr17:85,251,997...85,287,353

G

MDM2 proto-oncogene

increases phosphorylation
increases expression
multiple interactions

Pravastatin results in increased phosphorylation of MDM2 protein
Pravastatin results in increased expression of MDM2 protein
[Pravastatin results in increased phosphorylation of MDM2 protein] which results in increased degradation of TP53 protein; Sirolimus inhibits the reaction [Pravastatin results in increased phosphorylation of MDM2 protein]; U 0126 inhibits the reaction [Pravastatin results in increased phosphorylation of MDM2 protein]

NCBI chr 7:53,290,660...53,315,205
Ensembl chr 7:53,290,664...53,314,915

G

meiosis specific with OB-fold

decreases expression
increases expression

Pravastatin results in decreased expression of MEIOB mRNA
Pravastatin results in increased expression of MEIOB mRNA

NCBI chr10:13,833,170...13,865,684
Ensembl chr10:13,833,750...13,865,046

G

monoglyceride lipase

decreases expression
affects expression

Pravastatin results in decreased expression of MGLL mRNA
Pravastatin affects the expression of MGLL mRNA

NCBI chr 4:121,192,186...121,294,187
Ensembl chr 4:121,192,195...121,294,179

G

myo-inositol oxygenase

decreases expression

Pravastatin results in decreased expression of MIOX mRNA

NCBI chr 7:120,405,031...120,407,529
Ensembl chr 7:120,405,031...120,407,537

G

MIS18 kinetochore protein A

increases expression
decreases expression

Pravastatin results in increased expression of MIS18A mRNA
Pravastatin results in decreased expression of MIS18A mRNA

NCBI chr11:29,968,030...29,981,058
Ensembl chr11:29,967,701...29,981,062

G

malonyl-CoA decarboxylase

decreases expression
affects expression

Pravastatin results in decreased expression of MLYCD mRNA
Pravastatin affects the expression of MLYCD mRNA

NCBI chr19:47,447,931...47,463,794
Ensembl chr19:47,447,970...47,463,793

G

membrane metallo-endopeptidase

affects expression
decreases expression

Pravastatin affects the expression of MME mRNA
Pravastatin results in decreased expression of MME mRNA

NCBI chr 2:147,686,913...147,803,808
Ensembl chr 2:147,722,086...147,803,792

G

matrix metallopeptidase 14

decreases expression

Pravastatin results in decreased expression of MMP14 mRNA

NCBI chr15:27,887,795...27,897,020
Ensembl chr15:27,887,727...27,899,864

G

matrix metallopeptidase 2

decreases activity
decreases expression

Pravastatin results in decreased activity of MMP2 protein
Pravastatin results in decreased expression of MMP2 mRNA

NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870

G

matrix metallopeptidase 3

affects response to substance

MMP3 promoter polymorphism affects the susceptibility to Pravastatin

NCBI chr 8:4,640,397...4,653,963
Ensembl chr 8:4,640,416...4,653,961

G

matrix metallopeptidase 9

decreases activity
decreases expression

Pravastatin results in decreased activity of MMP9 protein
Pravastatin results in decreased expression of MMP9 mRNA

NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120

G

MSS51 mitochondrial translational activator

decreases expression
increases expression

Pravastatin results in decreased expression of MSS51 mRNA
Pravastatin results in increased expression of MSS51 mRNA

NCBI chr15:3,805,240...3,819,385
Ensembl chr15:3,807,516...3,819,385

G

myostatin

increases expression

Pravastatin results in increased expression of MSTN protein

NCBI chr 9:48,452,533...48,458,933
Ensembl chr 9:48,452,533...48,458,933

G

mechanistic target of rapamycin kinase

increases phosphorylation

Pravastatin results in increased phosphorylation of MTOR protein

NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311

G

mevalonate diphosphate decarboxylase

increases expression

Pravastatin results in increased expression of MVD mRNA

NCBI chr19:50,496,366...50,506,429
Ensembl chr19:50,496,367...50,507,971

G

nuclear factor, erythroid 2

increases expression

Pravastatin results in increased expression of NFE2 mRNA

NCBI chr 7:134,382,758...134,395,364
Ensembl chr 7:134,382,761...134,390,108

G

nicotinamide N-methyltransferase

increases expression
decreases expression

Pravastatin results in increased expression of NNMT mRNA
Pravastatin results in increased expression of NNMT protein
Pravastatin results in decreased expression of NNMT mRNA

PMID:27225895 PMID:33073877

NCBI chr 8:48,928,663...48,947,734
Ensembl chr 8:48,933,598...48,946,655

G

nitric oxide synthase 2

multiple interactions

Pravastatin inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]; Pravastatin inhibits the reaction [Palmitic Acid results in increased expression of NOS2 mRNA]; Pravastatin inhibits the reaction [Poly I-C results in increased expression of NOS2 mRNA]

NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210

G

nitric oxide synthase 3

multiple interactions
increases phosphorylation

[Resveratrol co-treated with Pravastatin] results in increased phosphorylation of NOS3 protein; Pravastatin promotes the reaction [NOS3 protein binds to NOS3 protein]; Pravastatin promotes the reaction [olmesartan results in increased activity of and results in increased phosphorylation of NOS3 protein]; Pravastatin results in increased activity of and results in increased phosphorylation of NOS3 protein
Pravastatin results in increased phosphorylation of NOS3 protein

PMID:17170375 PMID:17188708

NCBI chr 4:10,793,834...10,814,170
Ensembl chr 4:10,793,834...10,814,166

G

nuclear receptor subfamily 0, group B, member 2

decreases expression

Pravastatin results in decreased expression of NR0B2 mRNA

NCBI chr 5:145,779,294...145,782,609
Ensembl chr 5:145,779,294...145,782,609

G

NAD(P) dependent 3-beta-hydroxysteroid dehydrogenase NSDHL

increases expression

Pravastatin results in increased expression of NSDHL mRNA

NCBI chr X:150,775,034...150,807,161
Ensembl chr X:150,775,080...150,807,142

G

oxidized low density lipoprotein receptor 1

increases expression

Pravastatin results in increased expression of OLR1 mRNA

NCBI chr 4:162,926,436...162,949,057
Ensembl chr 4:162,926,439...162,948,523

G

origin recognition complex, subunit 1

affects expression
decreases expression

Pravastatin affects the expression of ORC1 mRNA
Pravastatin results in decreased expression of ORC1 mRNA

NCBI chr 5:123,324,273...123,348,375
Ensembl chr 5:123,324,315...123,348,375

G

P2Y receptor family member 10B

affects expression

Pravastatin affects the expression of P2RY10B mRNA

NCBI chr X:72,255,526...72,281,013
Ensembl chr X:72,238,713...72,281,012

G

protocadherin beta 5

increases expression

Pravastatin results in increased expression of PCDHB4 mRNA

NCBI chr18:29,024,315...29,032,183
Ensembl chr18:29,028,382...29,053,259

G

proprotein convertase subtilisin/kexin type 9

increases expression

Pravastatin results in increased expression of PCSK9 mRNA

NCBI chr 5:121,211,278...121,233,688
Ensembl chr 5:121,211,278...121,233,688

G

phosphatidylcholine transfer protein

decreases expression

Pravastatin results in decreased expression of PCTP mRNA

NCBI chr10:74,808,887...74,856,260
Ensembl chr10:74,808,887...74,849,867

G

phosphodiesterase 4A

decreases expression
increases expression

Pravastatin results in decreased expression of PDE4A mRNA
Pravastatin results in increased expression of PDE4A mRNA

NCBI chr 8:19,690,816...19,753,538
Ensembl chr 8:19,703,290...19,751,961

G

pyruvate dehydrogenase kinase 4

affects expression
increases expression

Pravastatin affects the expression of PDK4 mRNA
Pravastatin results in increased expression of PDK4 mRNA

NCBI chr 4:33,591,796...33,601,798
Ensembl chr 4:33,589,799...33,601,850

G

phosphatidylethanolamine N-methyltransferase

decreases expression

Pravastatin results in decreased expression of PEMT mRNA

NCBI chr10:44,775,910...44,849,990
Ensembl chr10:44,775,911...44,850,013

G

peroxisomal biogenesis factor 11 alpha

decreases expression

Pravastatin results in decreased expression of PEX11A mRNA

NCBI chr 1:133,680,091...133,687,172
Ensembl chr 1:133,680,091...133,687,172

G

platelet factor 4

decreases expression

Pravastatin results in decreased expression of PF4 mRNA

NCBI chr14:17,298,304...17,299,220
Ensembl chr14:17,298,308...17,299,365

G

phospholipase A2 receptor 1

increases expression

Pravastatin results in increased expression of PLA2R1 mRNA

NCBI chr 3:44,883,943...45,013,793
Ensembl chr 3:44,883,943...45,013,660

G

phospholipid phosphatase related 1

decreases expression

Pravastatin results in decreased expression of PLPPR1 mRNA

NCBI chr 5:63,437,457...63,725,286
Ensembl chr 5:63,437,816...63,763,835

G

phosphomevalonate kinase

increases expression

Pravastatin results in increased expression of PMVK mRNA

NCBI chr 2:174,876,586...174,886,365
Ensembl chr 2:174,876,657...174,886,364

G

patatin-like phospholipase domain containing 7

decreases expression

Pravastatin results in decreased expression of PNPLA7 mRNA

NCBI chr 3:7,782,572...7,861,504
Ensembl chr 3:7,782,572...7,861,497

G

DNA polymerase epsilon 2, accessory subunit

affects expression
decreases expression

Pravastatin affects the expression of POLE2 mRNA
Pravastatin results in decreased expression of POLE2 mRNA

NCBI chr 6:87,674,702...87,712,723
Ensembl chr 6:87,674,702...87,699,305

G

peroxisome proliferator activated receptor alpha

increases expression
multiple interactions
affects localization

Pravastatin results in increased expression of PPARA protein
Pravastatin promotes the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]
Pravastatin affects the localization of PPARA protein
[[Pravastatin co-treated with pirinixic acid] co-treated with [RXRA protein co-treated with PPARA protein]] results in increased expression of HMOX1 mRNA; [Pravastatin co-treated with [RXRA protein co-treated with PPARA protein]] results in increased expression of HMOX1 mRNA; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [Pravastatin affects the localization of PPARA protein]; Pravastatin promotes the reaction [PPARA protein binds to HMOX1 promoter]

PMID:18812576 PMID:20368269

NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346

G

peroxisome proliferator-activated receptor gamma

multiple interactions

Pravastatin inhibits the reaction [[troglitazone binds to and results in increased activity of PPARG protein] which results in increased abundance of Cholesterol]

NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468

G

protein phosphatase, Mg2+/Mn2+ dependent, 1J

decreases expression
increases expression

Pravastatin results in decreased expression of PPM1J mRNA
Pravastatin results in increased expression of PPM1J mRNA

NCBI chr 2:192,278,597...192,283,883
Ensembl chr 2:192,278,517...192,283,882

G

protein kinase AMP-activated catalytic subunit alpha 1

increases activity

Pravastatin results in increased activity of PRKAA1 protein

NCBI chr 2:54,240,298...54,275,978
Ensembl chr 2:54,240,137...54,275,978

G

prion like protein doppel

decreases expression

Pravastatin results in decreased expression of PRND mRNA

NCBI chr 3:119,213,462...119,218,742
Ensembl chr 3:119,213,429...119,218,745

G

prostaglandin-endoperoxide synthase 2

increases expression

Pravastatin results in increased expression of PTGS2 protein

NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188

G

protein tyrosine phosphatase, receptor type, N

increases expression
affects expression

Pravastatin results in increased expression of PTPRN mRNA
Pravastatin affects the expression of PTPRN mRNA

NCBI chr 9:76,741,010...76,756,704
Ensembl chr 9:76,741,016...76,756,190

G

retinol dehydrogenase 11

increases expression

Pravastatin results in increased expression of RDH11 mRNA

NCBI chr 6:97,979,377...97,995,252
Ensembl chr 6:97,979,378...97,995,252

G

receptor accessory protein 1

affects expression
increases expression

Pravastatin affects the expression of REEP1 mRNA
Pravastatin results in increased expression of REEP1 mRNA

NCBI chr 4:103,746,004...103,862,347
Ensembl chr 4:103,745,633...103,862,338

G

retinol saturase

decreases expression

Pravastatin results in decreased expression of RETSAT mRNA

NCBI chr 4:104,653,306...104,662,069
Ensembl chr 4:104,653,155...104,668,310

G

regulator of G-protein signaling 16

decreases expression

Pravastatin results in decreased expression of RGS16 mRNA

NCBI chr13:65,887,668...65,892,862
Ensembl chr13:65,887,530...65,892,857

G

ring finger protein 186

decreases expression
affects expression

Pravastatin results in decreased expression of RNF186 mRNA
Pravastatin affects the expression of RNF186 mRNA

NCBI chr 5:151,210,492...151,211,716
Ensembl chr 5:151,210,492...151,211,716

G

Ras-related GTP binding D

decreases expression

Pravastatin results in decreased expression of RRAGD mRNA

NCBI chr 5:47,373,902...47,409,369
Ensembl chr 5:47,373,463...47,409,356

G

retinoid X receptor alpha

multiple interactions

[[Pravastatin co-treated with pirinixic acid] co-treated with [RXRA protein co-treated with PPARA protein]] results in increased expression of HMOX1 mRNA; [Pravastatin co-treated with [RXRA protein co-treated with PPARA protein]] results in increased expression of HMOX1 mRNA

NCBI chr 3:10,989,832...11,076,366
Ensembl chr 3:10,989,832...11,073,712

G

S100 calcium-binding protein A4

affects expression
increases expression

Pravastatin affects the expression of S100A4 mRNA
Pravastatin results in increased expression of S100A4 mRNA

NCBI chr 2:176,090,951...176,093,258
Ensembl chr 2:176,091,804...176,093,254

G

S100 calcium binding protein G

decreases expression

Pravastatin results in decreased expression of S100G mRNA

NCBI chr X:31,705,853...31,708,422
Ensembl chr X:31,705,866...31,708,433

G

spermidine/spermine N1-acetyltransferase family member 2

decreases expression

Pravastatin results in decreased expression of SAT2 mRNA

NCBI chr10:54,340,756...54,343,507
Ensembl chr10:54,340,372...54,343,224

G

stearoyl-CoA desaturase

increases expression

Pravastatin results in increased expression of SCD mRNA

NCBI chr 1:243,269,745...243,282,878
Ensembl chr 1:243,269,747...243,282,562

G

stearoyl-Coenzyme A desaturase 2

increases expression

Pravastatin results in increased expression of SCD2 mRNA

NCBI chr 1:243,169,171...243,182,231
Ensembl chr 1:243,169,236...243,182,232

G

selectin P

decreases expression

Pravastatin results in decreased expression of SELP protein

NCBI chr13:76,476,229...76,511,846
Ensembl chr13:76,476,295...76,511,845

G

serpin family B member 1A

decreases expression

Pravastatin results in decreased expression of SERPINB1A mRNA

NCBI chr17:31,590,695...31,599,102
Ensembl chr17:31,590,677...31,599,102

G

secreted frizzled-related protein 1

increases expression

Pravastatin results in increased expression of SFRP1 mRNA

NCBI chr16:68,575,763...68,614,180
Ensembl chr16:68,575,763...68,614,286

G

shisa family member 4

increases expression

Pravastatin results in increased expression of SHISA4 mRNA

NCBI chr13:46,799,735...46,803,816
Ensembl chr13:46,799,772...46,803,998

G

sirtuin 1

increases phosphorylation

Pravastatin results in increased phosphorylation of SIRT1 protein

NCBI chr20:25,307,225...25,329,273
Ensembl chr20:25,306,917...25,329,260

G

solute carrier family 10 member 1

decreases expression

Pravastatin results in decreased expression of SLC10A1 mRNA

NCBI chr 6:100,613,045...100,626,670
Ensembl chr 6:100,613,045...100,626,670

G

solute carrier family 13 member 3

decreases expression

Pravastatin results in decreased expression of SLC13A3 mRNA

NCBI chr 3:154,141,878...154,204,604
Ensembl chr 3:154,141,872...154,204,606

G

solute carrier family 15 member 3

decreases expression

Pravastatin results in decreased expression of SLC15A3 mRNA

NCBI chr 1:207,492,365...207,507,158
Ensembl chr 1:207,492,365...207,507,157

G

solute carrier family 16 member 5

decreases expression
affects expression

Pravastatin results in decreased expression of SLC16A5 mRNA
Pravastatin affects the expression of SLC16A5 mRNA

NCBI chr10:100,707,434...100,721,338
Ensembl chr10:100,707,434...100,721,338

G

solute carrier family 17 member 1

decreases expression

Pravastatin results in decreased expression of SLC17A1 mRNA

NCBI chr17:41,219,461...41,255,199
Ensembl chr17:41,222,049...41,253,304

G

solute carrier family 17 member 3

decreases expression

Pravastatin results in decreased expression of SLC17A3 mRNA

NCBI chr17:41,270,804...41,300,132
Ensembl chr17:41,270,812...41,295,256

G

solute carrier family 22 member 5

affects expression
decreases expression

Pravastatin affects the expression of SLC22A5 mRNA
Pravastatin results in decreased expression of SLC22A5 mRNA

NCBI chr10:38,008,303...38,035,474
Ensembl chr10:38,008,311...38,035,309

G

solute carrier family 23 member 1

decreases expression

Pravastatin results in decreased expression of SLC23A1 mRNA

NCBI chr18:27,214,940...27,230,564
Ensembl chr18:27,216,281...27,230,697

G

solute carrier family 25 member 20

decreases expression

Pravastatin results in decreased expression of SLC25A20 mRNA

NCBI chr 8:109,365,056...109,386,512
Ensembl chr 8:109,365,002...109,386,512

G

solute carrier family 25, member 34

affects expression

Pravastatin affects the expression of SLC25A34 mRNA

NCBI chr 5:153,932,081...153,936,854

G

solute carrier family 25, member 42

decreases expression

Pravastatin results in decreased expression of SLC25A42 mRNA

NCBI chr16:19,213,914...19,251,990
Ensembl chr16:19,213,950...19,237,025

G

solute carrier family 27 member 2

decreases expression

Pravastatin results in decreased expression of SLC27A2 mRNA

NCBI chr 3:113,804,728...113,842,208
Ensembl chr 3:113,804,728...113,842,208

G

solute carrier family 2 member 4

decreases expression

Pravastatin results in decreased expression of SLC2A4 mRNA

NCBI chr10:54,666,015...54,671,581
Ensembl chr10:54,666,015...54,671,565

G

solute carrier family 34 member 2

decreases expression

Pravastatin results in decreased expression of SLC34A2 mRNA

NCBI chr14:57,910,931...57,930,236
Ensembl chr14:57,910,480...57,930,436

G

solute carrier family 9 member B2

affects expression
increases expression

Pravastatin affects the expression of SLC9B2 mRNA
Pravastatin results in increased expression of SLC9B2 mRNA

NCBI chr 2:223,726,982...223,761,234
Ensembl chr 2:223,736,354...223,761,225

G

solute carrier organic anion transporter family, member 1a4

affects transport
decreases expression

SLCO1A4 protein affects the transport of Pravastatin
Pravastatin results in decreased expression of SLCO1A4 protein

PMID:19833843 PMID:24909372

NCBI chr 4:174,710,004...174,764,810
Ensembl chr 4:174,710,004...175,254,573

G

solute carrier organic anion transporter family, member 1A5

increases expression
decreases expression

Pravastatin results in increased expression of SLCO1A5 mRNA
Pravastatin results in decreased expression of SLCO1A5 mRNA

NCBI chr 4:175,172,390...175,254,598
Ensembl chr 4:174,710,004...175,254,573

G

solute carrier organic anion transporter family member 1B2

multiple interactions

Pravastatin inhibits the reaction [SLCO1B3 protein results in increased uptake of Mesalamine]; Pravastatin inhibits the reaction [SLCO1B3 protein results in increased uptake of Sulfobromophthalein]

NCBI chr 4:174,551,463...174,619,988
Ensembl chr 4:174,551,480...174,619,981

G

solute carrier organic anion transporter family, member 2b1

multiple interactions

Pravastatin inhibits the reaction [SLCO2B1 protein results in increased uptake of Mesalamine]; Pravastatin inhibits the reaction [SLCO2B1 protein results in increased uptake of Sulfobromophthalein]

NCBI chr 1:153,959,288...154,007,294
Ensembl chr 1:153,959,293...154,007,353

G

solute carrier organic anion transporter family, member 4a1

increases expression

Pravastatin results in increased expression of SLCO4A1 mRNA

NCBI chr 3:167,559,177...167,578,307
Ensembl chr 3:167,559,316...167,578,305

G

small integral membrane protein 3

increases expression

Pravastatin results in increased expression of SMIM3 mRNA

NCBI chr18:53,930,019...53,982,339
Ensembl chr18:53,930,020...53,957,416

G

synaptosome associated protein 25

multiple interactions

[LDLR gene mutant form results in increased susceptibility to Pravastatin] which results in decreased expression of SNAP25 protein

NCBI chr 3:124,041,898...124,123,761
Ensembl chr 3:124,041,898...124,123,760

G

suppressor of cytokine signaling 3

increases expression

Pravastatin results in increased expression of SOCS3 protein

NCBI chr10:103,193,909...103,197,322
Ensembl chr10:103,193,537...103,197,787

G

sperm associated antigen 5

affects expression
decreases expression

Pravastatin affects the expression of SPAG5 mRNA
Pravastatin results in decreased expression of SPAG5 mRNA

NCBI chr10:63,198,717...63,216,746
Ensembl chr10:63,198,768...63,216,745

G

Spi-C transcription factor

decreases expression
increases expression

Pravastatin results in decreased expression of SPIC mRNA
Pravastatin results in increased expression of SPIC mRNA

NCBI chr 7:23,069,815...23,077,517
Ensembl chr 7:23,069,821...23,077,548

G

steroid 5 alpha-reductase 2

decreases expression

Pravastatin results in decreased expression of SRD5A2 mRNA

NCBI chr 6:21,426,225...21,465,727
Ensembl chr 6:21,426,215...21,462,112

G

ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 3

decreases expression

Pravastatin results in decreased expression of ST8SIA3 mRNA

NCBI chr18:57,754,349...57,760,839
Ensembl chr18:57,754,347...57,760,839

G

StAR-related lipid transfer domain containing 4

increases expression

Pravastatin results in increased expression of STARD4 mRNA

NCBI chr18:24,814,683...24,830,024
Ensembl chr18:24,817,107...24,830,024

G

signal transducer and activator of transcription 1

multiple interactions

Pravastatin inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of STAT1 protein]

NCBI chr 9:49,419,561...49,459,969
Ensembl chr 9:49,419,340...49,588,540

G

signal transducer and activator of transcription 3

decreases phosphorylation

Pravastatin results in decreased phosphorylation of STAT3 protein

NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057

G

syntaxin 1A

multiple interactions

[LDLR gene mutant form results in increased susceptibility to Pravastatin] which results in decreased expression of STX1A protein

NCBI chr12:21,641,971...21,670,022
Ensembl chr12:21,641,969...21,669,930

G

sulfotransferase family 1C member 2A

affects expression
decreases expression

Pravastatin affects the expression of SULT1C2 mRNA
Pravastatin results in decreased expression of SULT1C2 mRNA

NCBI chr 9:6,873,697...6,904,736
Ensembl chr 9:6,874,249...6,904,734

G

sulfotransferase family 1E member 1

decreases expression

Pravastatin results in decreased expression of SULT1E1 mRNA

NCBI chr14:20,422,324...20,439,562
Ensembl chr14:20,422,324...20,439,275

G

sulfotransferase family 2A member 1

decreases expression

Pravastatin results in decreased expression of SULT2A1 mRNA

NCBI chr 1:75,451,178...75,508,113
Ensembl chr 1:74,911,100...75,508,134

G

testis expressed 12

decreases expression

Pravastatin results in decreased expression of TEX12 mRNA

NCBI chr 8:50,908,161...50,913,202
Ensembl chr 8:50,909,052...50,913,217

G

thrombomodulin

affects expression
increases expression

Pravastatin affects the expression of THBD mRNA
Pravastatin results in increased expression of THBD mRNA

NCBI chr 3:135,863,366...135,867,018
Ensembl chr 3:135,862,835...135,867,193

G

TIMP metallopeptidase inhibitor 1

decreases expression

Pravastatin results in decreased expression of TIMP1 mRNA

NCBI chr X:1,212,969...1,217,714
Ensembl chr X:1,212,972...1,217,664

G

TIMP metallopeptidase inhibitor 2

decreases expression

Pravastatin results in decreased expression of TIMP2 mRNA

NCBI chr10:103,541,199...103,590,611
Ensembl chr10:103,531,505...103,590,611

G

TLC domain containing 4

decreases expression

Pravastatin results in decreased expression of TLCD4 mRNA

NCBI chr 2:209,284,873...209,360,156
Ensembl chr 2:209,289,732...209,341,353

G

transmembrane 7 superfamily member 2

increases expression

Pravastatin results in increased expression of TM7SF2 mRNA

NCBI chr 1:203,355,930...203,360,287
Ensembl chr 1:203,355,931...203,360,270

G

transmembrane protein 139

increases expression
decreases expression

Pravastatin results in increased expression of TMEM139 mRNA
Pravastatin results in decreased expression of TMEM139 mRNA

NCBI chr 4:71,147,072...71,149,151
Ensembl chr 4:71,146,724...71,167,399

G

transmembrane protein 164

decreases expression
increases expression

Pravastatin results in decreased expression of TMEM164 mRNA
Pravastatin results in increased expression of TMEM164 mRNA

NCBI chr X:106,288,019...106,448,642
Ensembl chr X:106,289,371...106,448,640

G

transmembrane protein 205

decreases expression

Pravastatin results in decreased expression of TMEM205 mRNA

NCBI chr 8:20,452,092...20,458,011
Ensembl chr 8:20,452,092...20,457,828

G

tumor necrosis factor

multiple interactions
increases expression

Pravastatin inhibits the reaction [LEP gene mutant form results in increased expression of TNF mRNA]; Pravastatin inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; Pravastatin promotes the reaction [[Lipopolysaccharides co-treated with TNF] results in increased abundance of Nitric Oxide]; Pravastatin promotes the reaction [[Lipopolysaccharides co-treated with TNF] results in increased expression of IL6 protein]
Pravastatin results in increased expression of TNF mRNA

PMID:17729120 PMID:18323514 PMID:27225895

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

TNF superfamily member 18

affects expression

Pravastatin affects the expression of TNFSF18 mRNA

NCBI chr13:73,833,478...73,907,249
Ensembl chr13:73,831,252...73,843,169

G

troponin T2, cardiac type

increases expression

Pravastatin results in increased expression of TNNT2 mRNA

NCBI chr13:47,267,325...47,285,390
Ensembl chr13:47,267,204...47,285,388

G

tumor protein p53

multiple interactions

[Pravastatin results in increased phosphorylation of MDM2 protein] which results in increased degradation of TP53 protein; Pravastatin inhibits the reaction [Fluorouracil results in decreased degradation of TP53 protein]; Pravastatin inhibits the reaction [leptomycin B results in decreased degradation of TP53 protein]; Pravastatin inhibits the reaction [lopinavir-ritonavir drug combination results in increased expression of TP53 protein]; Pravastatin inhibits the reaction [Ritonavir results in increased expression of TP53 protein]
Pravastatin inhibits the reaction [Cisplatin results in increased expression of TP53 protein]

PMID:15625077 PMID:20650967 PMID:20884875

NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524

G

tetraspanin 13

increases expression

Pravastatin results in increased expression of TSPAN13 mRNA

NCBI chr 6:52,738,748...52,765,503
Ensembl chr 6:52,738,758...52,765,547

G

tubulin, alpha 1A

increases expression

Pravastatin results in increased expression of TUBA1A mRNA

NCBI chr 7:130,113,214...130,116,880
Ensembl chr 7:130,081,032...130,196,186

G

UDP glucuronosyltransferase 2 family, polypeptide B1

decreases expression

Pravastatin results in decreased expression of UGT2B1 mRNA

NCBI chr14:21,024,035...21,035,784
Ensembl chr14:21,024,006...21,035,986

G

urocanate hydratase 1

decreases expression

Pravastatin results in decreased expression of UROC1 mRNA

NCBI chr 4:122,844,933...122,876,584
Ensembl chr 4:122,844,926...122,876,591

G

vesicle-associated membrane protein 2

multiple interactions

[LDLR gene mutant form results in increased susceptibility to Pravastatin] which results in decreased expression of VAMP2 protein

NCBI chr10:53,793,581...53,797,815
Ensembl chr10:53,793,923...53,797,809

G

vanin 1

decreases expression

Pravastatin results in decreased expression of VNN1 mRNA

NCBI chr 1:21,537,084...21,547,395
Ensembl chr 1:21,537,094...21,547,395

G

zinc finger CCCH type containing 12A

increases expression
decreases expression

Pravastatin results in increased expression of ZC3H12A mRNA
Pravastatin results in decreased expression of ZC3H12A mRNA

NCBI chr 5:137,376,562...137,385,351
Ensembl chr 5:137,376,564...137,385,351

resolvin D2

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

C-C motif chemokine ligand 2

multiple interactions

resolvin D2 inhibits the reaction [Lipopolysaccharides results in increased secretion of CCL2 protein]

NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226

G

C-X-C motif chemokine ligand 2

multiple interactions

resolvin D2 inhibits the reaction [Dextran Sulfate results in increased expression of CXCL2 protein]

NCBI chr14:17,181,030...17,183,075
Ensembl chr14:17,181,062...17,183,075

G

C-X-C motif chemokine ligand 3

multiple interactions

resolvin D2 inhibits the reaction [Dextran Sulfate results in increased expression of CXCL1 protein]

NCBI chr14:17,287,727...17,289,451
Ensembl chr14:17,270,146...17,289,511

G

intercellular adhesion molecule 1

multiple interactions

resolvin D2 inhibits the reaction [Dextran Sulfate results in increased expression of ICAM1 mRNA]

NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438

G

interferon gamma

multiple interactions

resolvin D2 inhibits the reaction [Lipopolysaccharides results in increased secretion of IFNG protein]

NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375

G

interleukin 1 beta

multiple interactions

resolvin D2 inhibits the reaction [Dextran Sulfate results in increased expression of IL1B protein]

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 6

multiple interactions

resolvin D2 inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein]

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

integrin subunit alpha L

multiple interactions

resolvin D2 inhibits the reaction [Dextran Sulfate results in increased expression of ITGAL mRNA]

NCBI chr 1:181,918,183...181,955,735
Ensembl chr 1:181,918,183...181,955,732

G

myeloperoxidase

multiple interactions

resolvin D2 inhibits the reaction [Dextran Sulfate results in increased activity of MPO protein]; resolvin D2 inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased activity of MPO protein]

NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819

G

NFKB inhibitor alpha

multiple interactions

resolvin D2 inhibits the reaction [Dextran Sulfate results in increased expression of NFKBIA mRNA]

NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941

G

prostaglandin-endoperoxide synthase 2

multiple interactions

resolvin D2 inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 mRNA]

NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188

G

RELA proto-oncogene, NF-kB subunit

multiple interactions

resolvin D2 inhibits the reaction [Dextran Sulfate results in increased activity of RELA protein]

NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484

G

tumor necrosis factor

multiple interactions

resolvin D2 inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]; resolvin D2 inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

vascular cell adhesion molecule 1

multiple interactions

resolvin D2 inhibits the reaction [Dextran Sulfate results in increased expression of VCAM1 mRNA]

NCBI chr 2:204,038,120...204,057,852
Ensembl chr 2:204,038,114...204,057,958

Term paths to the root

Path 1
Term	Annotations
CHEBI ontology	19901
chemical entity	19899
atom	19899
nonmetal atom	19822
carbon atom	19775
organic molecular entity	19775
olefinic compound	16990
allylic alcohol	967
secondary allylic alcohol	333
(+)-(1(10)E,4E,6S,7R)-germacradien-6-ol	0
(+)-isoepoxydon	0
(13R,14S)-dihydroxy-(4Z,7Z,9E,11E,16Z,19Z)-docosahexaenoic acid	0
(18R)-resolvin E3	0
(18S)-resolvin E1	0
(18S)-resolvin E2	0
(2E,5S,6E,8E,10E)-5-hydroxydodeca-2,6,8,10-tetraenal	0
(3R,5R)-7-[(1S,2S,6S,8S,8aR)-6,8-dihydroxy-2-methyl-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]-3,5-dihydroxyheptanoic acid +	303
(4S)-2,3-dehydroleucocyanidin	0
(4S)-2,3-dehydroleucopelargonidin	0
(4S)-4,16-dihydroxyretinoic acid	0
(4Z,7Z,10S,11E,13Z,15E,17S,19Z)-10,17-dihydroxydocosahexaenoic acid	0
(4Z,7Z,10Z,12E,14R,16Z,19Z)-14,22-dihydroxydocosahexaenoic acid	0
(4Z,7Z,10Z,12E,14R,16Z,19Z,21R)-dihydroxydocosahexaenoic acid	0
(4Z,7Z,10Z,12E,14R,16Z,19Z,21S)-dihydroxydocosahexaenoic acid	0
(4Z,7Z,10Z,12E,14S,16Z)-14-hydroxydocosapentaenoic acid	0
(4Z,7Z,10Z,12E,14S,16Z,19Z)-14,22-dihydroxydocosahexaenoic acid	0
(4Z,7Z,10Z,12E,14S,16Z,19Z,21S)-dihydroxydocosahexaenoic acid	0
(4Z,7Z,10Z,13Z,15E,17S)-17-hydroxydocosapentaenoic acid	0
(4Z,7Z,10Z,13Z,15E,19Z)-17-hydroxydocosahexaenoic acid +	17
(4Z,7Z,10Z,14E,16Z,19Z)-13-hydroxydocosahexaenoic acid	0
(5S)-hydroxy-(15S)-hydroperoxy-(6E,8Z,11Z,13E)-icosatetraenoic acid	0
(5S,6R)-dihydroxy-(15S)-hydroperoxy-(7E,9E,11Z,13E)-icosatetraenoic acid	0
(5Z,11Z,14Z)-8,9-dihydroxyicosatrienoic acid +	0
(5Z,8Z,11Z)-14,15-dihydroxyicosatrienoic acid +	0
(6E,8Z,11Z,13E,15S)-15-hydroxy-5-oxoicosatetraenoic acid	0
(7R,14S)-dihydroxy-(4Z,8E,10E,12Z,16Z,19Z)-docosahexaenoic acid	0
(7R,14S)-dihydroxy-(8E,10E,12Z,16Z,19Z)-docosapentaenoic acid	0
(7S,14S)-dihydroxy-(4Z,8E,10E,12Z,16Z,19Z)-docosahexaenoic acid	0
(7S,14S)-dihydroxy-(4Z,8E,10Z,12E,16Z,19Z)-docosahexaenoic acid	0
(8S)-cystein-S-yl-(7R,17S)-dihydroxy-(4Z,9,11,13Z,15E,19Z)-docosahexaenoic acid	0
(8S)-glutathionyl-(7R,17S)-dihydroxy-(4Z,9,11,13Z,15E,19Z)-docosahexaenoic acid	0
(8S)-glycinylcystein-S-yl-(7R,17S)-dihydroxy-(4Z,9,11,13Z,15E,19Z)-docosahexaenoic acid	0
(9Z,12Z)-11-hydroxyoctadecadienoic acid	0
(E)-4-hydroxynon-2-en-1-ol	0
(E)-dec-3-en-2-ol	0
(Z)-6-amino-2-hydroxy-4-(2-oxovinyl)hept-3-enedioic acid	0
(Z,S)-cinerolone	0
(Z,S)-jasmolone	0
1,4,4,7a-tetramethyl-2,4,5,7a-tetrahydro-1H-inden-2-ol	0
10-HETE	0
10-epi-pyriculol	0
11 hydroxy-(14R,15S)-epoxy-(5Z,8Z,12E)-icosatrienoic acid	0
11,12,15-trihydroxy-(5Z,8Z,13E)-icosatrienoic acid	0
11,14,15-trihydroxy-(5Z,8Z,12E)-icosatrienoic acid	0
11-O-acetylcyathatriol	0
12,20-dioxoleukotriene B4	0
13,14(S)-dihydroxy-(7Z,9E,11E,16Z,19Z)-docosapentaenoic acid	0
13,14,15-trihydroxy-(5Z,8Z,11Z)-icosatrienoic acid	0
13-HETE +	0
13-hydroxy-14,15-epoxy-(5Z,8Z,11Z)-icosatrienoic acid +	0
14(S),21-dihydroxy-(7Z,10Z,12E,16Z,19Z)-docosapentaenoic acid	0
14-HDoHE +	0
16,16-dimethylprostaglandin E2	8
16-HETE +	0
16-oxoresolvin D2	0
17-oxoresolvin D1	0
18-hydroxycarbocyclic thromboxane A2	0
18-hydroxyleukotriene B4	0
18-hydroxythromboxane A2	0
19-hydroxycarbocyclic thromboxane A2	0
19-hydroxyleukotriene B4	0
19-hydroxyprostaglandin I2	0
19-hydroxythromboxane A2	0
2,3,4,5-tetranor-thromboxane B1	0
2,3-dinor-TXB1	0
2-[(9S,11R)-epidioxy-(15S)-hydroxy-(5Z,13E)-prostadienoyl]-sn-glycero-3- phosphocholine	0
2-[(9S,11R)-epidioxy-(15S)-hydroxy-(5Z,13E)-prostadienoyl]-sn-glycero-3-phosphoethanolamine	0
2-hydroxy-3-butenyldesulfoglucosinolate	0
2-trans-4'-dihydroabscisic acid	0
20-hydroxyprostaglandin A1	0
20-hydroxyprostaglandin E1	0
20-hydroxyprostaglandin E2	0
3-deoxycapsidiol	0
3beta-hydroxy-15,16-epoxydolabrene	0
3beta-hydroxycostunolide	0
5,20-diHEPE	0
5-hydroxy-3-methylfuran-2(5H)-one	0
6-isopropenyl-4,4a-dimethyl-2,3,4,4a,5,6,7,8-octahydronaphthalen-2-ol +	0
7-HETE	0
7-oxoresolvin D2	0
9-cis-4-hydroxyretinoic acid	0
Avermectin B2a aglycone	0
TX-1875	0
all-trans-4,16-dihydroxyretinoic acid	0
all-trans-4,18-dihydroxyretinoic acid	0
all-trans-4-hydroxyretinal	0
all-trans-4-hydroxyretinoic acid +	9
aspirin-triggered protectin D1	0
aspirin-triggered resolvin D1	0
aspirin-triggered resolvin D2	0
aspirin-triggered resolvin D3	0
aspirin-triggered resolvin D4	0
aspirin-triggered resolvin D5	0
aspirin-triggered resolvin D6	0
aurafuron A	0
auxin a	0
beraprost	10
biscognienyne B	0
carbocyclic thromboxane A2 +	2
cyathadiol	0
cyathatriol +	0
dihydropyriculariol	0
dihydropyriculol	0
fostriecin	4
hawkinsin	0
laulimalide	0
marinolic acid C	0
piericidin A	1
preterpestacin I	0
prostaglandin A3	0
prostaglandin D2 1-glyceryl ester	0
prostaglandin D2 2-glyceryl ester	0
prostaglandin E2 1-glyceryl ester	0
prostaglandin E2 2-glyceryl ester	0
prostaglandin F1alpha alcohol	0
prostaglandin F2alpha 2-glyceryl ester	0
prostaglandin I2 2-glyceryl ester	0
prostaglandin J3 +	0
protectin D1 +	0
pyriculariol	0
pyriculol +	0
reedsmycin A	0
reedsmycin B	0
reedsmycin C	0
reedsmycin D	0
reedsmycin E	0
reedsmycin F	0
resolvin D2	14
resolvin D3	0
resolvin D4	0
resolvin D5	0
resolvin D6	0
resolvin E2	0
resolvin E3	0
westerdijkin A	0
Path 2
Term	Annotations
CHEBI ontology	19901
subatomic particle	19899
composite particle	19899
hadron	19899
baryon	19899
nucleon	19899
atomic nucleus	19899
atom	19899
main group element atom	19838
p-block element atom	19838
chalcogen	19589
oxygen atom	19561
oxygen molecular entity	19561
hydroxides	19368
organic hydroxy compound	18980
alcohol	15749
allylic alcohol	967
secondary allylic alcohol	333
(+)-(1(10)E,4E,6S,7R)-germacradien-6-ol	0
(+)-isoepoxydon	0
(13R,14S)-dihydroxy-(4Z,7Z,9E,11E,16Z,19Z)-docosahexaenoic acid	0
(18R)-resolvin E3	0
(18S)-resolvin E1	0
(18S)-resolvin E2	0
(2E,5S,6E,8E,10E)-5-hydroxydodeca-2,6,8,10-tetraenal	0
(3R,5R)-7-[(1S,2S,6S,8S,8aR)-6,8-dihydroxy-2-methyl-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]-3,5-dihydroxyheptanoic acid +	303
(4S)-2,3-dehydroleucocyanidin	0
(4S)-2,3-dehydroleucopelargonidin	0
(4S)-4,16-dihydroxyretinoic acid	0
(4Z,7Z,10S,11E,13Z,15E,17S,19Z)-10,17-dihydroxydocosahexaenoic acid	0
(4Z,7Z,10Z,12E,14R,16Z,19Z)-14,22-dihydroxydocosahexaenoic acid	0
(4Z,7Z,10Z,12E,14R,16Z,19Z,21R)-dihydroxydocosahexaenoic acid	0
(4Z,7Z,10Z,12E,14R,16Z,19Z,21S)-dihydroxydocosahexaenoic acid	0
(4Z,7Z,10Z,12E,14S,16Z)-14-hydroxydocosapentaenoic acid	0
(4Z,7Z,10Z,12E,14S,16Z,19Z)-14,22-dihydroxydocosahexaenoic acid	0
(4Z,7Z,10Z,12E,14S,16Z,19Z,21S)-dihydroxydocosahexaenoic acid	0
(4Z,7Z,10Z,13Z,15E,17S)-17-hydroxydocosapentaenoic acid	0
(4Z,7Z,10Z,13Z,15E,19Z)-17-hydroxydocosahexaenoic acid +	17
(4Z,7Z,10Z,14E,16Z,19Z)-13-hydroxydocosahexaenoic acid	0
(5S)-hydroxy-(15S)-hydroperoxy-(6E,8Z,11Z,13E)-icosatetraenoic acid	0
(5S,6R)-dihydroxy-(15S)-hydroperoxy-(7E,9E,11Z,13E)-icosatetraenoic acid	0
(5Z,11Z,14Z)-8,9-dihydroxyicosatrienoic acid +	0
(5Z,8Z,11Z)-14,15-dihydroxyicosatrienoic acid +	0
(6E,8Z,11Z,13E,15S)-15-hydroxy-5-oxoicosatetraenoic acid	0
(7R,14S)-dihydroxy-(4Z,8E,10E,12Z,16Z,19Z)-docosahexaenoic acid	0
(7R,14S)-dihydroxy-(8E,10E,12Z,16Z,19Z)-docosapentaenoic acid	0
(7S,14S)-dihydroxy-(4Z,8E,10E,12Z,16Z,19Z)-docosahexaenoic acid	0
(7S,14S)-dihydroxy-(4Z,8E,10Z,12E,16Z,19Z)-docosahexaenoic acid	0
(8S)-cystein-S-yl-(7R,17S)-dihydroxy-(4Z,9,11,13Z,15E,19Z)-docosahexaenoic acid	0
(8S)-glutathionyl-(7R,17S)-dihydroxy-(4Z,9,11,13Z,15E,19Z)-docosahexaenoic acid	0
(8S)-glycinylcystein-S-yl-(7R,17S)-dihydroxy-(4Z,9,11,13Z,15E,19Z)-docosahexaenoic acid	0
(9Z,12Z)-11-hydroxyoctadecadienoic acid	0
(E)-4-hydroxynon-2-en-1-ol	0
(E)-dec-3-en-2-ol	0
(Z)-6-amino-2-hydroxy-4-(2-oxovinyl)hept-3-enedioic acid	0
(Z,S)-cinerolone	0
(Z,S)-jasmolone	0
1,4,4,7a-tetramethyl-2,4,5,7a-tetrahydro-1H-inden-2-ol	0
10-HETE	0
10-epi-pyriculol	0
11 hydroxy-(14R,15S)-epoxy-(5Z,8Z,12E)-icosatrienoic acid	0
11,12,15-trihydroxy-(5Z,8Z,13E)-icosatrienoic acid	0
11,14,15-trihydroxy-(5Z,8Z,12E)-icosatrienoic acid	0
11-O-acetylcyathatriol	0
12,20-dioxoleukotriene B4	0
13,14(S)-dihydroxy-(7Z,9E,11E,16Z,19Z)-docosapentaenoic acid	0
13,14,15-trihydroxy-(5Z,8Z,11Z)-icosatrienoic acid	0
13-HETE +	0
13-hydroxy-14,15-epoxy-(5Z,8Z,11Z)-icosatrienoic acid +	0
14(S),21-dihydroxy-(7Z,10Z,12E,16Z,19Z)-docosapentaenoic acid	0
14-HDoHE +	0
16,16-dimethylprostaglandin E2	8
16-HETE +	0
16-oxoresolvin D2	0
17-oxoresolvin D1	0
18-hydroxycarbocyclic thromboxane A2	0
18-hydroxyleukotriene B4	0
18-hydroxythromboxane A2	0
19-hydroxycarbocyclic thromboxane A2	0
19-hydroxyleukotriene B4	0
19-hydroxyprostaglandin I2	0
19-hydroxythromboxane A2	0
2,3,4,5-tetranor-thromboxane B1	0
2,3-dinor-TXB1	0
2-[(9S,11R)-epidioxy-(15S)-hydroxy-(5Z,13E)-prostadienoyl]-sn-glycero-3- phosphocholine	0
2-[(9S,11R)-epidioxy-(15S)-hydroxy-(5Z,13E)-prostadienoyl]-sn-glycero-3-phosphoethanolamine	0
2-hydroxy-3-butenyldesulfoglucosinolate	0
2-trans-4'-dihydroabscisic acid	0
20-hydroxyprostaglandin A1	0
20-hydroxyprostaglandin E1	0
20-hydroxyprostaglandin E2	0
3-deoxycapsidiol	0
3beta-hydroxy-15,16-epoxydolabrene	0
3beta-hydroxycostunolide	0
5,20-diHEPE	0
5-hydroxy-3-methylfuran-2(5H)-one	0
6-isopropenyl-4,4a-dimethyl-2,3,4,4a,5,6,7,8-octahydronaphthalen-2-ol +	0
7-HETE	0
7-oxoresolvin D2	0
9-cis-4-hydroxyretinoic acid	0
Avermectin B2a aglycone	0
TX-1875	0
all-trans-4,16-dihydroxyretinoic acid	0
all-trans-4,18-dihydroxyretinoic acid	0
all-trans-4-hydroxyretinal	0
all-trans-4-hydroxyretinoic acid +	9
aspirin-triggered protectin D1	0
aspirin-triggered resolvin D1	0
aspirin-triggered resolvin D2	0
aspirin-triggered resolvin D3	0
aspirin-triggered resolvin D4	0
aspirin-triggered resolvin D5	0
aspirin-triggered resolvin D6	0
aurafuron A	0
auxin a	0
beraprost	10
biscognienyne B	0
carbocyclic thromboxane A2 +	2
cyathadiol	0
cyathatriol +	0
dihydropyriculariol	0
dihydropyriculol	0
fostriecin	4
hawkinsin	0
laulimalide	0
marinolic acid C	0
piericidin A	1
preterpestacin I	0
prostaglandin A3	0
prostaglandin D2 1-glyceryl ester	0
prostaglandin D2 2-glyceryl ester	0
prostaglandin E2 1-glyceryl ester	0
prostaglandin E2 2-glyceryl ester	0
prostaglandin F1alpha alcohol	0
prostaglandin F2alpha 2-glyceryl ester	0
prostaglandin I2 2-glyceryl ester	0
prostaglandin J3 +	0
protectin D1 +	0
pyriculariol	0
pyriculol +	0
reedsmycin A	0
reedsmycin B	0
reedsmycin C	0
reedsmycin D	0
reedsmycin E	0
reedsmycin F	0
resolvin D2	14
resolvin D3	0
resolvin D4	0
resolvin D5	0
resolvin D6	0
resolvin E2	0
resolvin E3	0
westerdijkin A	0

paths to the root